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1  Introduction 1
1  Introduction 
1.1  Dendritic cells 
Dendritic cells (DC) are specialized leukocytes that are present in virtually all 
organs of mammalian bodies. Their key function is the sampling and processing 
of antigens, which they then present in major histocompatibility complex (MHC) 
II molecules to cells of the adaptive immune system, mainly effector CD4-
positive T cells. A couple of decades ago, macrophages were believed to be the 
main antigen-presenting cells [1]. In the last years, it has been established that 
indeed DC are mainly responsible for fulfilling this role in mammalian organisms 
[2-6], although other cells of the immune system, such as macrophages, 
monocytes, and B cells, are also capable of presenting antigens to a lesser 
degree. Furthermore, in recent years, other possible antigen-presenting cells 
have emerged, such as hepate stellate cells and myofibroblasts [7, 8]. However, 
the role of these cells and their potential participation in mounting a specific 
immune response has to be further defined. 
The life cycle of DC is depicted in Fig. 1.1 (adapted from [3]). DC in the various 
organs most probably arise from blood-borne precursor cells. The nature of 
these precursor cells has long been a matter of debate. For human peripheral 
blood monocytes it has been established for many years that they can be 
differentiated in vitro to functional DC by adding appropiate cytokines such as 
GM-CSF and IL-4 [9-12]. This in vitro differentiation of human monocytes into 
DC can also be achieved by transendothelial migration; in this model, the 
migrated monocytes gained a DC phenotype, whereas the non-migrating 
monocytes differentiated into macrophages [13]. When examined in an in vivo 
mouse model, murine monocytes have been shown to be able to differentiate 
into functional DC, too [14]. Peripheral blood monocytes in both humans and 
mice have been shown to comprise several subsets with putative different 
functions [15, 16].  Recently, Fogg et al. have identified a circulating bone 
marrow-derived cell population in mice that is the progenitor cell for 
macrophages and DC [17]. However, the exact origin of DC in peripheral 
organs has not been delineated completely, since all of the putative precursor 
cells show a high in vivo plasticity [18]. Furthermore, monocytes also have the 
1  Introduction 2
potential to differentiate into specialized macrophages at various sites of the 
body [15, 19-21]. 
 
 
 
 
Fig. 1.1: The life cycle of dendritic cells  
Circulating DC precursor cells enter tissues as immature DC. They can also directly encounter
pathogens (e.g. viruses) that induce secretion of cytokines (e.g. IFN-α), which in turn can
activate eosinophils, macrophages (MF), and natural killer (NK) cells. After antigen capture,
immature DCs migrate to lymphoid organs where, after maturation, they display peptide-major
histocompatibility complexes, which allow selection of rare circulating antigen-specific
lymphocytes. These activated T cells help DC in terminal maturation, which allows lymphocyte
expansion and differentiation. Activated T lymphocytes migrate and can reach the injured
tissue, because they can traverse inflamed epithelia. Helper T cells secrete cytokines, which
permit activation of macrophages, NK cells, and eosinophils. Cytotoxic T cells eventually lyse
the infected cells. B cells become activated after contact with T cells and DC and then migrate
into various areas where they mature into plasma cells, which produce antibodies that
neutralize the initial pathogen. It is believed that, after interaction with lymphocytes, DC die by
apoptosis. Figure and legend were adapted from Banchereau et al. [3]. 
1  Introduction 3
In peripheral organs, DC encounter many different antigens, which they sample 
and process for antigen presentation. In this stage, they have a high phagocytic 
activity, but express low levels of MHC II and costimulatory molecules that are 
necessary for initiating a T cell response, such as B7-1 (CD80), B7-2 (CD86), 
and CD40. Consequently, at this stage DC exhibit a weak stimulatory activity 
towards T cells. After ingestion of the antigen, DC process the antigens and 
present them in MHC II molecules. Simultaneously, DC undergo maturation, 
thereby loosing their phagocytic activity and upregulating the expression of 
costimulatory molecules for a highly efficient antigen presentation to T cells. 
The maturation process is accompanied by a migration to the regional lymph 
nodes, where the antigen presentation and T cell proliferation takes place. 
In addition to initiating an immune response, DC are also capable of 
suppressing the clonal expansion of T cells specific for the presented antigen. 
DC that suppress specific T cell proliferation have also been termed 
“tolerogenic DC” [22]. For this, DC produce and secrete a wide variety of 
cytokines and chemokines of both immunostimulatory (e.g., TNF-α, IL-12) or 
immunosuppressive action (e.g., IL-10, TGF-β) [3, 16]. Among many other 
ways, the in vivo generation of immunosuppressive DC can be initiated by the 
phagocytosis of apoptotic cells via a suppression of IL-12 production [23, 24] 
and by an upregulation of TGF-β production [25]. Independent of IL-10 or TGF-
β secretion, the hepatocyte growth factor (HGF) is able to suppress vital DC 
functions like antigen presentation, thereby blocking the development of asthma 
in a mouse model [26]. Furthermore, DC are targets for classical 
immunosuppressive agents, such as rapamycin, and are depleted by the use of 
immunosuppressive drugs such as prednisolone, e.g., in patients after kidney 
transplantation [27-31].  
By this, DC have been shown to be critical players in deciding whether the 
immune system mounts an effective immune response or rather dampens a 
response that might be detrimental for the organism. For many years it had 
been assumed that a mature DC phenotype is necessarily linked to the 
stimulation of antigen-specific T cells, thus mounting a specific immune 
response. However, in the last years it could be shown by many authors that 
DC that are phenotypically mature are capable of acting as tolerogenic DC 
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rather then stimulating an immune response against the presented antigen. 
Thus, this view on the term ‘maturation’ has been questioned recently, and it 
has been proposed to use it merely descriptively for DC that express high levels 
of MHC II, CD80, CD86, and CD40 molecules [32]. In the following, this 
terminology will be used throughout as a phenotypic rather than functional 
description of DC. Figure 1.2 depicts the current view on the different ways in 
which DC can shape the immune response to a respective antigen (adapted 
from [32]). 
 
Fig. 1.2: Model of dendritic cell effector function 
This view of DC function supposes that immature DC can give rise to multiple types of ‘effector’
DC that instruct distinct T-cell fates, including immunity, tolerance and immune deviation.
Maturation refers to the changes that accompany immature DC transition to a given effector
state in response to environmental signals of exogenous (for example, microbial) or
endogenous (for example, cytokines, hormones and dying cells) origin. CTL, cytotoxic T
lymphocyte; IL-17, interleukin-17; TCR, T-cell receptor; TH, T helper. Figure and legend were
adapted from Reis e Sousa [32]. 
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The DC pool in mice and humans consists of several subsets, which have been 
intensively investigated in the past years [33-35]. The “classical” DC subsets 
express high levels of αx integrin (CD11c) and MHC II as well as costimulatory 
molecules, as outlined above. Most prominent constitutents of the “classical” 
DC pool in mice are the myeloid subset, characterized by the expression of the 
αM integrin (CD11b), and the lymphoid subset (CD11bnegative CD8αpositive). 
Distinct from these, recently the plasmacytoid DC subset has been described, 
which expresses only intermediate levels of CD11c, but high levels of the B cell 
marker B220 (CD45R). Most importantly, these plasmacytoid DC are the major 
producers of type 1 interferons (Interferon-A and –B) and are therefore also 
termed interferon-producing cells (IPC). A special DC subset, the Langerhans 
cells, is located to the skin. The various DC subsets can be further 
differentiated, e.g. by expression of CD4 and DEC-205 (CD205), and are found 
in different phenotypic compositions in the various organs [33, 34]. Recently, 
functional differences in regard to antigen presentation and the stimulation 
between the DC subsets have been described. However, the exact role of the 
interplay of DC subsets remains to be further delineated [35, 36]. 
 
Apart from the molecules needed for antigen capture, uptake, processing and 
presentation, DC also express many receptors of the innate immune system, 
namely virtually all Toll-like receptors (TLR). The TLR belong to the expanding 
group of pattern recognition receptors (PRR); these germline-encoded 
receptors recognize conserved motifs of pathogens, such as lipopolysaccharide 
(LPS) and other compounds of bacterial cell walls, single-stranded RNA, and 
unmethylated CpG DNA [37]. These conserved pathogen motifs are usually 
referred to as pathogen-associated molecular patterns (PAMPs). The 
recognition of PAMPs via PRR represents one of the phylogenetically oldest 
immune pathways and is of crucial importance for the proper function of the 
immune system [37]. The expression of TLR by DC has been intensively 
investigated over the past years. In general, DC express virtually all known 
TLR, but their expression differs between DC subsets and anatomical locations 
[38]. Activation of DC via TLR stimulation is critical for the induction of DC 
maturation and the initiation of an effective immune response. Furthermore, DC 
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can produce various proinflammatory cytokines such as TNF-α, IL-6, IL-12, and 
IL-8 or the murine homologues, KC and MIP-2, respectively. Thereby, DC are 
indispensably integrated into both the innate and the adaptive immune system 
and are the main cells to brigde these two crucial parts of the immune system 
[38, 39]. However, the role of DC for the initiation and the course of acute 
inflammatory reactions remains poorly understood, while the role of DC in 
inflammations dominated by the adaptive immune system has been extensively 
addressed. The putative importance of DC also in both compartimentalized and 
systemic acute inflammations is underlined by the fact that, in addition to their 
well established role in organ-specific inflammatory responses, recent studies 
indicated an important role for DC in sepsis. In humans who died of severe 
sepsis, the number of DC in the spleen is dramatically reduced [40]. In vivo 
depletion of DC aggravates the course of sepsis in a mouse model [41], and 
survival can be improved in mouse models by adoptive transfer of DC or by in 
vivo transfection of DC and overexpression of IL-10 [41-43]. These findings 
support a concept of a DC-based intervention strategy to treat and circumvene 
a severe immunosuppression during sepsis, a condition that is correlated with a 
high mortality (reviewed in [44]. 
 
1.2  Dendritic cells in the lung 
DC of the lung are ideally situated in close proximity to alveolar epithelium and 
resident alveolar macrophages to sample and process inhaled antigens, thus 
rendering these cells critical to the initiation or suppression of adaptive immune 
responses of the lung. In both the conducting airways and the alveoli, they form 
interdigitating networks with their typical processi [45-48]. In the small intestine, 
DC have been shown to form balloon-like processi into the lumen that are 
important for antigen sampling [49, 50]. These DC processi also exist in the 
lungs of mice (H.-C. Reinecker, personal communication); their role for lung 
immunity, however, has not been delineated yet. Under steady-state conditions, 
DC in the lung display a high motility and volatility with an approximate turnover 
time of ≤ 2 days [45]. In case of inflammation, DC are rapidly recruited to the 
lung and the conducting airways in response to a broad spectrum of stimuli, 
including live and heat-killed bacteria, viruses, and ovalbumin [51-55]. Their 
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transporting of antigen to the regional lymph nodes is a critical step in mounting 
an immune response against the respective antigen. This transportation and 
antigen presentation is performed by special migratory DC [56]. DC are critical 
players in initiating and maintaining an effective immune response, e.g., in 
tuberculosis [57] and Aspergillus fumigatus infection [58]. However, most of the 
studies on lung DC have been performed in asthma models (reviewed in [48]). 
In contrast, little is known about the role of DC in acute lung inflammation in 
response to inhaled PAMPs like LPS or in the early phase of bacterial 
pneumonia. 
One major obstacle in studying DC function in the lung is that at present there is 
no system for selective depletion of DC without depleting other cell populations. 
Approaches to deplete DC from the lung have been undertaken using thymidine 
kinase-transgenic mice, where DC are depleted after ganciclovir application 
[59]. Another approach [60] used mice that carry a transgenic receptor for 
diphteria toxin under the control of the CD11c promotor [61]. The major 
disadvantage of these systems, at least when studying early inflammatory 
responses in the lung, is that other immune cells, namely alveolar 
macrophages, are also depleted. Therefore, for analyzing DC function in acute 
lung inflammation, a different system had to be established. 
 
1.3  Fms-like tyrosine kinase 3-ligand (Flt3L) 
Fms-like tyrosine kinase 3-ligand (Flt3L), also termed fetal liver kinase-2 (flk-2), 
is a hematopoietic growth factor that displays an important impact on 
proliferation and mobilization of multiple leukocyte types and their precursor 
cells, including B cell progenitor and myeloid precursor cells, NK cells, and DC 
[62]. After cloning of the gene encoding the human and murine Flt3L [63-65], it 
could be shown that the repeated systemic administration of recombinant 
human Flt3L into mice evokes a rapid and high mobilization of hematopoietic 
precursor cells and an increase in neutrophils, monocytoid cells and 
lymphocytes in the peripheral blood and in multiple organs, including the spleen 
[66]. Furthermore, Maraskovsky et al. demonstrated that the administration of 
recombinant human Flt3L elicits a dramatic increase in numbers functional DC 
in mice. This increase takes place in multiple organs, including the lung [67]. 
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The DC accumulating in the lung of Flt3L-treated mice belong mainly to the 
myeloid subset and display a more, although not complete, mature phenotype 
[68]. In rats, also a single intratracheal dose of Flt3L has been shown to 
increase the DC numbers [69]. 
Flt3L has been shown to synergize with a variety of other cytokines and growth 
factors in the generation of DC [70]. In marked contrast to the in vitro 
differentiation of DC from bone marrow, where granulocyte macrophage-colony 
stimulating factor (GM-CSF) is of crucial importance [71], in the in vivo situation, 
Flt3L in combination with granulocyte-colony stimulating factor (G-CSF) and 
other cytokines seems to be the most important growth factor for DC 
differentiation [70, 72]. 
Like in mice, the systemic administration of Flt3L to humans results in a drastic 
increase in circulating numbers of DC [73, 74]. These findings open the 
perspective of using Flt3L as an immunomodulatory agent in diseases like 
cancer. Indeed, in several mouse studies, the administration of Flt3L has been 
shown to exert a beneficial effect of inflammatory diseases such as asthma [75], 
infections with the intracellular pathogen Listeria monocytogenes [76, 77], 
viruses like herpes simplex virus [77], and Pseudomonas aeruginosa sepsis 
[78]. The combination of irradation and systemic Flt3L application also improved 
the survival in a mouse model of metastatic lung cancer [79]. Furthermore, Flt3L 
treatment can revert an endotoxin tolerance-related immune paralysis [80]. 
However, in some instances, Flt3L application also leads to adverse effects, like 
in a murine tuberculosis model [81].  
In the lung, until now the administration of Flt3L has only be addressed in the 
context of chronic inflammation and infection, like asthma and tuberculosis [76, 
81]. Little is known about the lung DC pathobiology in mice in response to 
treatment with bacterial toxins or with bacteria typically causing an acute 
pneumonia. Likewise, the effect of systemic Flt3L application on the lung’s 
inflammatory phenotype in acute pneumonia situation has not been delineated. 
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1.4   Pneumonia, acute lung injury (ALI), and adult respiratory 
distress syndrome (ARDS) 
Pneumonia is one of the clinically most important infections and one of the 
leading causes of mortality worldwide. In western industrial countries the 
incidence is estimated as 1-11/1000 people per year. Although most patients 
can be sufficiently treated outside the hospital, a significant percentage of the 
pneumonia patients requires hospitalization [82-84]. A growing problem in 
treatment of pneumonia is the increasing prevalence of bacteria which are 
resistant to standard antibiotics [83, 84]. Therefore, the need for non-antibiotic 
based treatment options is emerging. This is underlined by the observation in 
the USA that after antibiotic treatment became available, mortality dropped from 
ca. 100/100.000 people per year in 1920 to approximately 40/100.000 people 
per year in 1950; however, since then mortality due to pneumonia has not 
changed significantly despite the introduction of a wide variety of new antibiotics 
and substantial improvement of supportive medical treatment [85]. On a 
worldwide scale, lung infections are the leading cause of mortality [86, 87]. 
Pneumonia can be caused by a variety of pathogens, including bacteria, 
viruses, fungi, and parasites. The prevalence of the different pathogens 
depends on many factors, e.g., age, immunosuppression, and concomitant 
diseases. The majority of pneumonia cases, however, is caused by bacteria 
[82, 84]. 
Acute bacterial pneumonia is characterized by an early production of 
proinflammatory cytokines, such as TNF-α and IL-6, and chemokines which 
attract immune cells, namely polymorphnuclear granulocytes (PMN) and, to a 
lesser extent, monocytes [88, 89]. In later phases, the infiltrating leukocytes 
have to be cleared from the lung parenchyma. At all stages, the delicate organ 
structure has to be conserved to maintain lung function for ventilation and gas 
exchange. This has to be achieved by balancing effective host defense and 
clearing of pathogens on one hand and maintainance of the lung structural 
integrity on the other hand [87].  
The acute lung injury (ALI) and its severe form, the adult respiratory distress 
syndrome (ARDS), were initially described in 1967 [90]. It presents as a severe 
failure of the lung organ function and is characterized by a loss of the 
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pulmonary barrier function, resulting in pulmonary edema formation, the 
destruction of the fragile lung structure and subsequent severe hypoxemia [91-
93]. ARDS can arise from both intrapulmonary conditions, such as pneumonia 
or aspiration, and extrapulmonary causes, e.g., trauma, major surgery, or 
sepsis of different origins [92, 93].  
Pathophysiologically, ARDS is characterized by an excessive production of 
proinflammatory cytokines and recruitment of leukocytes to the alveolar space 
[94]. An important and early recognized feature of ARDS is also a severe 
dysregulation in the surfactant system, an observation that has prompted many 
trials analyzing the possible replacement of surfactant components in ARDS 
patients [93, 95-98]. A central role in the development of ARDS is often 
assigned to the uncontrolled influx and action of PMN [99]. However, it is a 
common clinical observation that full-blown ARDS also can develop in 
neutropenic patients [100, 101]. Although many efforts have been undertaken in 
the past decades to characterize the molecular and cellular events leading to 
ARDS, and many details have been elucidated, there are still many open 
questions. Most importantly, the overall mortality in ARDS has decreased since 
its initial description 30 years ago from 50-70% to 35-40%, but this decrease is 
probably mainly due to improved supportive care leading to less extrapulmonary 
complications rather than to a causal treatment of the lung disorder [93]. 
Although various therapeutic approaches have been tested in clinical trials, 
including surfactant replacement, corticosteroids, inhibition of neutrophil 
elastase and others, a specific treatment for this lung disorder could not be 
established yet, and therapeutic regimens for ARDS are based on treatment of 
the underlying reasons of lung failure and an optimized supportive care  [93, 
102, 103]. Therefore, a better understanding of the complex molecular and 
cellular events in the pathogenesis of ARDS is crucial for the development of 
new, causal treatment approaches of this severe disease. 
Animal models are a well established tool in pneumonia and ARDS research. 
Among the model animals, mice are by far the most used species, and are used 
for many aspects of research, e.g., in pathogenesis, therapeutic interventions, 
and drug delivery [104-106]. The use of mice as model animals offers many 
advantages, e.g. their well characterized immune system with a uniquely vast 
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array of experimental tools available; the availability of inbred strains minimizing 
the influence of genetic variations on the course of infections; and the wide pool 
of genetically modified mice [104]. 
 
1.5  Klebsiella pneumoniae 
The gram-negative bacterium Klebsiella pneumoniae belongs to the family of 
Enterobacteriaceae, and is the clinically most important species of the genus 
Klebsiella. It is found both in the environment, e.g., in water or soil, and as a 
colonizing bacterium of the mucosa of many mammalian organisms, including 
humans [107]. It is well known for causing severe pneumonia, especially in 
alcoholics and immunocompromized patients, and other infections such as 
urinary tract infections. Among the community-acquired pneumonia cases, it 
accounts for a minor but significant part of cases with often severe clinical 
course and high mortality [108, 109]. 
Furthermore, it is a major agent of hospital-acquired infections including 
ventilation-associated pneumonia and sepsis [107, 108] and seems to be 
spread easily from patient to patient despite strict fulfillment of standard hygiene 
procedures [110]. This becomes increasingly important since a growing part of 
the clinical isolates expresses extended-spectrum beta-lactamases (ESBLs), a 
virulence factor rendering these bacteria resistant to all beta-lactame antibiotics 
[111]. 
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1.6  Aims of the study 
In marked contrast to their well characterized role in chronic lung inflammations 
like asthma or tuberculosis, little is known about the lung DC pathobiology in 
acute lung inflammation. It is generally assumed that resident alveolar 
macrophages are central in the initiation and propagation of lung inflammation 
that develops in response to bacterial toxins and infections. However, some 
essential features of lung DC make these cells a highly attractive target 
population in acute lung inflammation: Their  anatomical location with close 
proximity to epithelia, vessels, and alveolar macrophages; their unique 
equipment with TLR and other sensing molecules of the innate immune system; 
their capability of producing large amounts of proinflammatory cytokines; and 
their central position at the interface of innate and adaptive immune system. Up 
to now, the in vivo contribution of lung DC under acute inflammatory conditions 
has not been examined. 
Since there is no satisfying model for selective depletion of lung DC, an 
overexpression model using the systemic application of Flt3L was used to 
enrich lung DC numbers. With this, the following questions were addressed in 
the present study to define the contribution of DC to lung acute inflammation: 
 
1. What adhesion molecules do lung DC use in the setting of Flt3L elicited 
recruitment? 
2. What is the role of Flt3L elicited lung DC in the early phase of the lung 
inflammatory response to a prototypic inhaled PAMP, 
lipopolysaccharide (LPS)? 
3. What is the role of Flt3L elicited lung DC in the early phase of a 
bacterial pneumonia? 
 
To answer these questions, at first a model of Flt3L elicited lung DC 
accumulation was established and characterized. Then, the adhesion molecules 
that mediate lung DC accumulation were analyzed by the use of monoclonal 
antibodies, and a selective inhibition of Flt3L elicited DC accumulation was 
achieved. Using this model, the role of Flt3L elicited lung DC in acute lung 
inflammation in response to lipopolysaccharide (LPS) and intratracheal infection 
with Klebsiella pneumoniae was analyzed. 
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2  Materials and Methods 
2.1  Mice 
Wild-type C57BL/6 mice (18-22 g) were purchased from Charles River 
(Sulzfeld, Germany) and were kept under conventional conditions with free 
access to food and water in the central animal facility of the Justus-Liebig-
Universität Gießen (Zentrales Tierlabor). C3H/HEJ mice as donors for spleen 
lymphocytes were bred under conventional conditions in the central animal 
facility. All animal experiments were approved by and in accordance with the 
guidelines of the local government authority (Regierungspräsidium Gießen). 
 
2.2  Reagents  
Flt3L (Fms-like tyrosine kinase-3 ligand) was a kind gift from Amgen Inc. 
(Thousand Oaks, CA, USA). Lyophilized Flt3L was reconstituted in sterile water 
to a stock concentration of 1 mg/ml and stored at –80°C. For in vivo application, 
stocks were diluted with PBS-/- + 0.1% HSA to a final concentration of 100 
µg/ml. 
 
The other reagents used for the experiment are listed in the following: 
 
Amphotericin B for cell culture Gibco. Paisly, UK 
Aqua dest., sterile Braun, Melsungen, Germany 
β-Mercaptoethanol 50 mM (for cell culture) Gibco. Paisly, UK 
β-Mercaptoethanol (for RNA isolation) Sigma, Taufkirchen, Germany 
Escherichia coli O111:B4  Calbiochem, La Jolla, CA, USA 
lipopolysaccharide (LPS), ultrapure  
Ethanol (70% and 100%) Riedel de Haën, Seelze, Germany 
Ethidium bromide solution (10 mg/ml)  Carl Roth (Karlsruhe, Germany) 
FITC-labeled bovine albumin Sigma (Taufkirchen, Germany) 
Giemsa’s azur eosin methylenblue Merck, Darmstadt, Germany 
Hank’s balanced salt solution (HBSS) PAA Laboratories, Pasching, 
Austria 
HEPES (2-(4-(2-Hydroxyethyl)-  Gibco. Paisly, UK 
1-piperacinyl)-ethansulfonic acid)   
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Human serum albumine (HSA) Sigma, Taufkirchen, Germany 
Isofluran (1-chloro-2,2,2-  Abbot, Wiesbaden, Germany 
trifluoroethyl-difluoromethyl ether)  
Ketavet® (Ketamine hydrochloride) Pharmacia & Upjohn, Erlangen, 
Germany 
Mouse serum,  Sigma, Taufkirchen, Germany 
inactivated for 30 min at 56°C     
May-Grünwald’s eosin methylen blue  Merck, Darmstadt, Germany 
MTT (3-(4,5-Dimethylthiazol-2-yl)-  Sigma, Taufkirchen, Germany 
2,5-diphenyltetrazoliumbromide)  
NaCl 0,9%, sterile Braun, Melsungen, Germany 
Na-Pyruvate for cell culture  Gibco. Paisly, UK 
Non-essential amino acids 100x Gibco, Paisly, UK 
Octagam® (human immunoglobulin G) Octapharma, Langenfeld, 
Germany  
PBS-/- (without Ca2+ and Mg2+) 10x PAA Laboratories, Pasching, 
Austria 
Penicillin-streptomycin for cell culture Gibco, Paisly, UK 
EDTA (Versen) 1% in PBS-/- Biochrom, Berlin, Germany 
Fetal calf serum (FCS),  Gibco. Paisly, UK 
inactivated for 30 min at 56°C  
RPMI-1640 PAA Laboratories, Pasching, 
Austria 
Rompun® (Xylazine hydrochloride) Bayer, Leverkusen, Germany 
Softasept® N Braun, Melsungen, Germany  
TissueTek OTC Sakura Finetek, Zoeterwoude,  
 The Netherlands 
Todd-Hewitt broth Becton Dickinson, Franklin Lakes, 
NJ, USA 
Tris-HCl Carl Roth, Karlsruhe, Germany 
Trypan blue solution 0.4% Gibco, Paisly, UK 
Tween 20 (Polyoxyethylene(20)-  Sigma, Taufkirchen, Germany 
-sorbitan-monolaurate)  
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2.3  Monoclonal antibodies 
The panel of anti-mouse monoclonal antibodies (mAbs) used for flow cytometric 
analyses, function-blocking experiments, and in vivo depletion of circulating 
neutrophils are listed in Table 2.1. All isotype controls were purchased from BD 
Biosciences (San Jose, CA, USA). For in vivo applications, only azide-free mAb 
preparations with a LPS content of < 0.01 ng/µg protein were used. 
 
Specificity Clone Isotype Label Source 
CD4 RM4-4 rat IgG2b FITC BD Biosciences 
CD8α 53-6.7 rat IgG2a biotinylated BD Biosciences 
CD11a M17/4 rat IgG2a purified Hybridoma (ATCC) [112] 
CD11a M17/4 rat IgG2a PE BD Biosciences 
CD11b M1/70 rat IgG2b purified Hybridoma (ATCC) [113] 
CD11b M1/70 rat IgG2b APC BD Biosciences 
CD11c N418 hamster PE-Cy5.5 Caltag 
CD11c HL3 hamster biotinylated BD Biosciences 
CD18 2E6 hamster purified Hybridoma (ATCC) [114] 
CD18 C71/16 rat IgG PE BD Biosciences 
CD19 1D3 rat IgG PE BD Biosciences 
CD45 30-F11 rat IgG2b FITC BD Biosciences 
CD45R/B220 RA3-6B2 rat IgG2a PE BD Biosciences 
CD49d PS/2 rat IgG2a purified Hybridoma (ATCC) [115] 
CD49d R1-2 rat IgG2b PE BD Biosciences 
CD49e 5H10-27 rat IgG2a PE BD Biosciences 
CD54/ICAM-1 YN1.1 rat IgG2a purified Hybridoma (ATCC) 
CD62L MEL-14 rat IgG2a PE BD Biosciences 
CD86 GL1 rat IgG2a PE BD Biosciences 
CD106/VCAM-1 M/K-2.7 rat IgG2a purified Hybridoma (ATCC) [115] 
CD162/PSGL-1 2PH1 rat IgG1 PE BD Biosciences 
CD205 NLDC-145 rat IgG2a Alexa647 Serotec (Oxford, UK) 
F4/80 CI:A3-1 rat IgG2b FITC Serotec (Oxford, UK) 
F4/80 CI:A3-1 rat IgG2b Alexa647 Serotec (Oxford, UK) 
GR-1 RB6-8C5 rat IgG2b PE BD Biosciences 
GR-1 RB6-8C5 rat IgG2b purified BD Biosciences 
I-A/I-E (MHC II) 2G9 rat IgG2a biotinylated BD Biosciences 
JAM-C CRAM-18 rat IgG2a purified Serotec (Oxford, UK) 
NK1.1 PK136 rat IgG2a APC BD Biosciences 
 
Table 2.1: List of monoclonal antibodies 
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Hybridoma cell lines were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA, USA) and were grown in 75 ml tissue culture flasks in 
RPMI-1640+20% FCS+glutamin+100 U/ml penicillin/streptomycin/amphotericin 
B. In the first passage, mouse peritoneal Mφ were added as feeder cells. 
Supernatants were harvested, centrifuged to remove cell debris, and sterile-
filtered through 0.2 µm pore filters. IgG was isolated using HyTrap 1 ml Protein 
G columns (Amersham). The eluted IgG solution was then dialyzed against 
PBS-/- over night. Protein content was assessed using a Bradford protein Kit 
(BioRad). Purity was checked by running samples of the antibody preparations 
on a standard PAGE electrophoresis. Activity was confirmed by flow cytometric 
analysis of mouse cells (leukocytes or alveolar epithelial cells) stained with the 
isolated antibody and a matching secondary antibody (anti-rat or anti-hamster-
PE, STAR-73 or STAR-79, respectively, both from Serotec, Oxford, UK), and 
compared to the staining with a primary-labeled mAb of the same specifity (see 
Table 2.1). LPS content in antibody preparations was < 0.01 ng/µg protein, as 
determined by chromogenic limulus amebocyte lysate test (BioWhittaker, 
Walkersville, MD, USA).  
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2.4  Treatment protocols 
2.4.1  Treatment with Flt3L and in vivo application of mAb 
Mice were treated systemically with Flt3L (10µg in 100 µl PBS/0.1% HSA) by 
daily subcutaneous injections into the hind leg using sterile single use injection 
syringes (Omnican 50, Braun, Melsungen, Germany). For this, mice were 
shortly anaesthesized by isofluran inhalation, and the hind leg was disinfected 
with Softasept®. Control mice received a daily injection of vehicle, i.e. 100 µl 
PBS/0.1% HSA. 
Additionally, in some experiments, mice simultaneously received intraperitoneal 
injections of function-blocking mAbs with specificity to various adhesion 
molecules or their receptors (100µg/mouse diluted in 100 µl sterile saline) at 
days 1, 3, 5, 7 and 9 of Flt3L application. Control mice received injections of 
matching isotype control antibodies. 
 
2.4.2  Intratracheal instillation of LPS 
To evaluate the role of lung DC in LPS-induced lung inflammation, mice were 
pretreated for nine days with subcutaneous injections of Flt3L or vehicle and 
concomitantly received function-blocking antibodies with specificity to various 
adhesion molecules or their receptors. On day 9, mice were anaesthezised by 
intramuscular application of tetrazoline hydrochloride (2,5 mg/kg; Rompun®, 
Bayer) and ketamine (50 mg/kg; Ketavet®, Pharmacia Upjohn) and 
subsequently challenged intratracheally with LPS (1 µg ultrapure LPS/mouse) 
for 24h. For this, the anaesthezised but breathing mice were placed on the 
back, and the ventral neck region was shaved. After disinfection with 
Softasept®, a longitudinal skin incision was made, and the trachea was 
carefully exposed by blunt preparation. A 26 gauge Abbocath catheter (Hospira, 
Donegal Town, Ireland) was inserted, and 1 µg of ultrapure LPS in 70 µl sterile 
saline per mouse was slowly injected. After removing the Abbocath catheter, 
the skin incision was closed with 6x0 vicryl sutures (Ethicon, Norderstedt, 
Germany). After the instillation, mice were set back to the cages with free 
access to food and water. 
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2.4.3  Infection experiments with Klebsiella pneumoniae 
The Klebsiella pneumoniae serotype 2 strain was purchased from ATCC (No 
43816).  K. pneumoniae were grown in Todd-Hewitt broth (BD Biosciences) for 
18-24 h. Determination of colony-forming units (CFU) was done by plating ten-
fold serial dilutions of bacterial suspensions on blood agar plates followed by 
incubation of the plates at 37°C for 18 hours and enumeration of the CFU. 
Bacteria were then diluted with PBS to the desired concentration (104 CFU/70 µl 
per mouse) that were used for intratracheal infection experiments on day 9 of 
Flt3L treatment. The procedure was in analogy to the intratracheal application of 
LPS (see 2.4.2) Subsequently, mice were killed, lungs were subjected to 
bronchoalveolar lavage, and lungs were removed for further analysis as 
described in the following (see 2.5). Cell-free BAL supernatants were stored at 
–20°C for cytokine measurements. BAL fluid cellular constituents were counted 
using a Neubauer hemocytometer and cell differentials were determined on 
Pappenheim-stained cytospin preparations (see 2.5). 
 
2.4.4  In vivo depletion of circulating neutrophils 
In selected experiments, both Flt3L- and vehicle-pretreated mice were made 
transiently neutropenic by intraperitoneal injections of anti-GR-1 mAb (5 
µg/mouse diluted in 100 µl saline) 24h prior to and at the time of intratracheal 
LPS instillation. This dose has previously been demonstrated to efficiently 
deplete circulating PMN, but not the GR-1-positive subset of circulating 
monocytes [116]. 
 
2.4.5  Peritoneal LPS injection 
For induction of peritoneal inflammation, mice received an intraperitoneal 
injection of 20 µg ultrapure LPS in a total volume of 100 µl sterile saline, or 
saline alone. 24 h later, mice were killed and subjected to peritoneal lavage 
using PBS/2 mM EDTA. Peritoneal lavage fluid was analyzed for cell numbers, 
differential cell counts, TNF-α and IL-12 levels, and subjected to flow cytometry, 
as described for the BAL fluid (see 2.5.1). 
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2.5  Analysis of mice 
2.5.1 Recovery of blood, spleens, bronchoalveloar lavage fluid, 
and mediastinal lymph nodes 
At the indicated time points, mice were killed by overdosed isofluran inhalation 
in an exsiccator (Schott, Mainz, Germany). After soaking the fur with 70% 
ethanol, the abdominal cavity was opened, blood was drawn from the Vena 
cava inferior and transferred to small EDTA-containing blood collection tubes 
(Sarstedt, Nümbrecht, Germany) to prevent blood clotting. Blood smears were 
prepared using one drop of blood. The rest of the blood was subjected to 
erythrolysis using 0.8% ammonium chloride solution. Erythrolysis was stopped 
by adding RPMI-1640/10% FCS. After centrifugation (10 min, 300 x g, 4°C), 
erythrolysis was repeated. Cells were again centrifuged, washed twice in RPMI-
1640, counted and then stained for flow cytometric analysis (see 2.5.3). All cell 
countings were performed using a standard Neubauer chamber. Cell viability in 
the various preparations was routinely > 97%, as assessed by trypan blue 
exclusion test.  
Spleens were removed, transferred to a Petri dish containing 5 ml of RPMI-
1640, cut into small pieces and homogenized with a syringe. After filtering 
through a 40 µm cell strainer (BD Falcon), cells were centrifuged (10 min, 300 x 
g, 4°C) and subjected to erythrolysis as described above. After washing, cells 
were counted and stained for flow cytometric analyis. 
For bronchoalveolar lavage (BAL), skin and tissue of the ventral neck were 
carefully removed, and the trachea was exposed. A 20 gauge cannula was 
inserted, and the lungs were lavaged with a total of 6 ml of PBS-/-/2 mM EDTA. 
The first 1.5 ml were put in a separate 15 ml Falcon tube. Samples were 
centrifuged (10 min, 400 x g, 4°C). The supernatant of the first 1.5 ml was 
stored at –20°C for subsequent analysis of proinflammatory cytokines and BAL 
fluid protein content. The rest of the supernatant was discarded, cells were 
resuspended in RPMI-1640, and counted. After preparation of cytospins using a 
cytocentrifuge (Cytospin 3, Shandon, Runcorn, UK), cells were stained for flow 
cytometric analysis. 
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After recovery of the BAL fluid, the chest cavity was opened. Mediastinal lymph 
nodes were carefully harvested and transferred to 1.5 ml Eppendorf tubes 
containing 200 µl of RPMI-1640 + 0.7 mg/ml Collagenase A (Roche, Mannheim, 
Germany) and 50 µg/ml DNAse I (Serva, Heidelberg, Germany). After 
incubation at 37°C, 5% CO2 for 60 min, lymph nodes were homogenized with a 
pipette and washed twice with RPMI-1640 (10 min, 300 x g, 4°C). After cell 
counting, cells were stained for flow cytometric analysis. 
Blood smears and cytospins were stained with Pappenheim (May-Grünwald-
Giemsa) stain and analyzed using a standard bright field microscope (Leica, 
Wetzlar, Germany). For differential cell counts, routinely 100 cells were 
counted. 
 
2.5.2  Isolation and identification of lung DC and lung Mφ 
Isolation and identification of lung DC was performed as described in detail 
previously [56, 117], with some modifications. Lungs were lavaged with PBS-/-/2 
mM EDTA as described above. Then, a small incision was made into the left 
atrium, and lungs were perfused with 20 ml HBSS via the right ventricle using a 
21 gauge injection cannula (Ecoflo Dispomed, Gelnhausen, Germany) until 
lungs were visually free of blood. After this, lungs were removed, transferred to 
sterile Petri dishes containing RPMI-1640 + 0.7 mg/ml Collagenase A (Roche, 
Mannheim, Germany) and 50 µg/ml DNAse I (Serva, Heidelberg, Germany), cut 
into small pieces and incubated for 90 min at 37°C, 5% CO2 with gentle 
shaking. Subsequently, the digested lung tissue was suspended with a syringe 
and filtered through a 200 µm and a 40 µm cell strainer (BD Biosciences), 
followed by two washing steps of the resultant single cell suspensions in HBSS 
and PBS/2mM EDTA/0.5% FCS. Subsequently, lung homogenate cells were 
resuspended in PBS/2mM EDTA/0.5% FCS, and incubated with an excess 
concentration of unspecific IgG (Octagam) to reduce non-specific antibody 
binding, and then stained with magnetic bead-conjugated anti-CD11c antibodies 
(Miltenyi Biotec, Bergisch Gladbach, Germany), followed by magnetic 
separation according to the manufacturer’s instructions. After washing in 
PBS/2mM EDTA/0.5% FCS, the resultant two major cell populations of lung 
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macrophages and lung DC were subjected to a detailed FACS analysis of cell 
surface antigen expression profiles (see 2.5.3). 
Identification of alveolar DC in BAL fluid specimen of Flt3L pretreated mice in 
the absence or presence of LPS was done by flow cytometry. Most of the cells 
with a monocytic morphology contained in BAL fluids of Flt3L or Flt3L plus LPS 
pretreated mice were found to be CD11chi, CD11bhi, MHCIImid-high and CD86pos, 
thus representing alveolar accumulating monocyte-derived myeloid dendritic 
cells. 
 
2.5.3  Flow cytometry and cell sorting 
All staining procedures were performed on flexible 96 well plates (BD Falcon) at 
4°C in the dark. Cells (1-5x105/ml) were washed in cold PBS/5% mouse serum. 
Unspecific antibody binding was blocked with CD16/CD32 (Fc-block, BD 
Pharmingen) or by adding an excess concentration of unspecific IgG 
(Octagam®, Octapharma GmbH, Germany). Cells were stained with 
fluorochrome-labeled primary antibodies diluted to working concentrations in 
PBS/10% inactivated mouse serum for 20 min and washed twice in cold 
PBS/5% mouse serum. Biotinylated primary antibodies were further incubated 
for 5 min with APC-Cy7-conjugated streptavidin, followed by washing twice in 
cold PBS/5% mouse serum. Flow cytometric analysis was performed using a 
FACSCanto flow cytometer (BD Biosciences). Cell sorting was performed with a 
FACSVantage SE flow cytometer equipped with a DiVA sort option and an 
argon-ion laser operating at 488 nm excitation wavelength and a HeNe laser 
operating at 633 nm excitation wavelength. The BD FACSDiVa software 
package was used for data analysis (BD Biosciences). For further analysis and 
preparations of figures of flow cytometric experiments, the WinMDI 2.8 software 
was used. 
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2.5.4  Immunohistochemistry 
Lungs were perfused with 20 ml HBSS until they were visually free of blood,  
inflated via the trachea with a 1:1 mixture of TissueTek OCT and PBS-/-, then 
removed en bloc, transferred to TissueTek OCT, and snap-frozen in liquid 
nitrogen and stored at –80°C until further processing. Lung tissue cryosections 
(7 µm) were prepared using a cryotom (Leica Instruments, Wetzlar, Germay), 
mounted on glass slides and dried overnight at room temperature. After fixing in 
ice-cold acetone (10 min), the slides were washed in TBS/0.1% Tween 20, and 
endogenous biotin was blocked with a biotin blocking system 
(DAKOCytomation, Hamburg, Germany). Hamster-anti-mouse CD11c mAb 
(HL3), rat-anti-mouse CD11b (M1/70, both BD Biosciences), rat-anti-mouse 
F4/80 (CI:A3-1, Serotec) and the respective isotype control Abs were 
approbiately diluted in background-reducing antibody diluent 
(DAKOCytomation), then pipettet to the tissue slides and incubated overnight at 
4°C in a humidified atmosphere. After washing with TBS/0.1% Tween 20, slides 
were incubated for 45 min at room temperature with biotinylated mouse-anti-
hamster IgG (BD Biosciences), or biotinylated goat-anti-rat IgG (DAKO), 
respectively,  followed by washing and a further incubation with alkaline 
phosphatase-conjugated streptavidin (DAKO). Immunohistochemical staining 
was developed using the Fast Red Kit (DAKO), and lung tissue sections 
counterstained with filtered hemalaun (Fluka, Taufkirchen, Germany) were 
mounted using Ultramount medium (DAKO). Slides were examined using a 
microscope equipped with a digital imaging unit (Leica, Wetzlar, Germany). 
 
2.5.5  ELISA and protein concentration measurement 
Cytokine concentrations in BAL fluids were determined using DuoSet ELISA 
plates (R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s 
instructions. Total protein concentration in BALF was measured using the 
Bradford reagent kit (BioRad, Hercules, CA, USA). Measurements were 
performed using an UVmax ELISA reader, and data were analyzed using the 
KC software package (both Molecular Devices, Sunnyvale, CA, USA). 
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2.5.6  SDS-PAGE of BAL fluid 
SDS polyacrylamide gel electrophoresis of total protein contained in BAL fluid 
was performed using 12% Criterion XT Bis-Tris gels (Bio-Rad, Hercules, CA, 
USA) at a constant voltage of 200 V for 1h. Gels were stained with Coomassie 
blue (Bio-Rad) for 1h. After destaining with water (3 x 15 min), densitometric 
analysis of the albumin band was performed using a GS-800TM Calibrated 
Densitometer and the 1-D analysis software Quantity One (both Bio-Rad). 
Relative densities were calculated in comparison to untreated control mice. 
 
2.5.7  FITC albumin leakage assay 
For the determination of lung leakage, in selected experiments mice received 
an injection of 1 mg FITC-labeled albumin in 100 µl of sterile saline via lateral 
tail veins. One hour later, mice were sacrificed, and cell-free BAL fluid 
supernatants were collected as described above. Serum was recovered after 
centrifugation (15 min at 1000 x g) from coagulated blood. FITC fluorescence 
(absorbance wavelength of 488 nm and emission wavelength of 520 ± 20 nm) 
was measured in undiluted BAL fluid and serum samples (diluted 1:100 in PBS) 
using a fluorescence spectrometer (FLx 800; Bio-Tek Instruments, Winooski, 
VT, USA). The lung permeability index is defined as the ratio of fluorescence 
signals of undiluted BAL fluid samples to fluorescence signals of 1:100 diluted 
serum samples [118]. 
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2.6.  Functional characterization of lung DC 
2.6.1 Allogenic mixed lymphocyte reaction and MTT test 
Untouched CD4-positive T cells for stimulation experiments were isolated from 
spleens of C3H/HEJ mice. Mice were killed by overdosed isoflurane inhalation, 
and spleens were harvested aseptically and transferred to sterile petri dishes 
into RPMI-1640 + 10% FCS. After mechanical disruption, spleens were 
homogenized using a sterile syringe and filtered over a 100 µm and a 40 µm 
cell strainer. Erythrocytes were lysed using a sterile-filtered 0.8% ammonium 
chloride solution. Spleen cells were washed twice in RPMI-1640 + 10% FCS 
(10 min, 300 x g, 4°C), transferred to a sterile 75 ml cell culture flask and 
incubated for 3 h at 37°C, 5% CO2. After the incubation, non-adherent cells 
were harvested, transferred to a 50 ml Falcon tube, washed twice in PBS/2mM 
EDTA/0.5% FCS (10 min, 300 x g, 4°C), and counted using a Neubauer 
chamber. Viability was assessed using trypan blue exclusion and was routinely 
> 97%. 1x108 cells were magnetically labeled using the Untouched CD4 Cell 
Isolation MACS Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to 
the manufacturer’s instructions. CD4 cells were separated using MACS LS 
columns. Purity was routinely >90% as confirmed by flow cytometric analysis 
using CD4-FITC antibodies (see Table 1). 
Lung DC, lung Mφ and lung PMN from C57BL/6 mice were flow-sorted as 
described in 2.5.3. Isolated CD4-positive T cells and sorted DC, lung Mφ and 
PMN were resuspended in complete RPMI (RPMI-1640 + 10% FCS + 1 mM 
sodium pyruvate + 1x non-essential amino acids + 10 mM HEPES + 50 µM β-
mercapto-ethanol + 100 U/ml penicillin-streptomycin). T cells (200.000 cells/well 
in a total volume of 200/µl) were pipetted to a 96-well flat bottom plate. Sorted 
DCs, AM, or PMN (20.000 cells/well) were added to the wells as indicated. Cells 
were incubated at 37°C and 5% CO2 for 3 days. 
MTT (tetrazolium bromide) was stored as a 5 mg/ml stock solution in PBS-/- at       
–20°C. For working dilutions, MTT was diluted to a final concentration of 0,175 
mg/ml in complete RPMI. For assessment and quantification of viable cells, 96-
well plates were centrifuged (3 min at 300 x g, 4°C). Medium was discarded, 
cells were resuspended in 200 µl of complete RPMI + MTT, and incubated for 
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90 min at 37°C, 5% CO2. After this, cells were pelleted (3 min at 300 x g, 4°C), 
the supernatant was discarded, and cells were fixed for 30 min with PBS-/- + 4% 
PFA at room temperature with continuous protection from light. After 
centrifugation of the cells (3 min at 300 x g, 4°C) and discarding of the 
supernatant, cells were dried for 15 min at room temperature under a fume 
hood. Tetrazolium crystals were solved in 200 µl/well isopropanol, and MTT 
absorption was assessed at λ=550 nm using a reference wave length of λ=620 
nm in an ELISA reader (see 2.5.5). Wells with 200 µl isopropanol only served as 
blank controls. MTT specific absorption (A550/620) of samples was calculated as 
Sample A550/620/mean A550/620 of blank controls. 
 
2.6.2  Sorting of DC and in vitro stimulation 
To assess the potential of lung DC and lung Mφ to produce proinflammatory 
cytokines in response to LPS challenge in vivo and in vitro, lung DC and Mφ 
were sorted according to their scatter and autofluorescence characteristics and 
CD11c expression profile, as described above. Sorted cells were pelleted and 
recovered in lysis buffer (Qiagen, Hilden, Germany).  In other experiments, 
sorted DC (1x105 cells/250 µl in RPMI/10% FCS) were incubated in 48 well 
polysterene plates in the absence or presence of ultrapure LPS (100 ng/ml, 6h, 
37°C/5% CO2). Subsequently, cells lysates were prepared and stored at –80°C 
for further gene expression analysis. 
 
2.6.3  RNA isolation, cDNA synthesis, and PCR 
RNA from sorted DC and lung Mφ as well es from lung homogenates was 
isolated using the RNeasy Micro Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. RNA content of the preparations was measured 
with a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE, 
USA). RNA was stored at –80°C until further processing. 
Primers used for conventional RT-PCR as well as quantitative RT-PCR (qRT-
PCR) were designed as intron-spanning primers. Primers were synthesized by 
Metabion (Martinsried, Germany) and are listed in Table 2.3. Synthesis of cDNA 
and RT-PCR were done using GeneAmp 2400 PCR machines (Perkin Elmer, 
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Waltham, MA, USA). All chemicals for PCR reaction were purchased from 
Invitrogen (Carlsbad, CA, USA), unless mentioned otherwise. 
The composition of the reaction for cDNA synthesis and the conditions for 
reaction are listed in Table 2.2. Each cDNA synthesis was done in a final 
sample volume of 25 µl (5 ng/µl final cDNA concentration). Before addition of 
the MMLV-RT, samples were denatured for 5 min at 70°C and then immediately 
stored on ice. For further PCR reactions, cDNA was diluted 1:5 (1 ng/µl final 
cDNA concentration). Stocks and working dilutions of cDNA were stored at –
20°C.  
 
Total RNA     125 ng 
Random hexamers     10 pmol 
dNTPs       10 mM 
5x first strand buffer     5 µl 
DTT       250 mM 
RNAse inhibitor      20 U 
MMLV reverse transcriptase    200 U 
H2O (molecular biology grade)   to a final volume of 25 µl 
Conditions for cDNA synthesis: 50 min at 37°C,  
followed by 5 min at 96°C, then 4°C. 
 
Table 2.2: cDNA synthesis 
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β-actin (amplicon size 104 bp) 
forward 5’-ACC CTA AGG CCA ACC GTG A-3’ 
reverse 5’-CAG AGG CAT ACA GGG ACA GCA-3’,  
Flt3L (amplicon size 133) 
forward 5’-ACA GTC CCA TCT CCT CCA AC-3’ 
reverse 5’-TAG GAA GAG GCT CCA CAA GG-3’ 
IL-12 p35 (amplicon size 94 bp) 
forward 5’-AGA CCA CAG ATG ACA TGG TGA-3’ 
reverse 5’-GTC CCG TGT GAT GTC TTC AT-3’ 
MIP-2 (amplicon size 89 bp) 
forward 5’-ATC CAG AGC TTG AGT GTG ACG C-3’ 
reverse 5’-AAG GCA AAC TTT TTG ACC GCC-3’ 
PBGD (amplicon size 138 bp) 
forward 5’-GGT ACA AGG CTT TCA GCA TCG-3’  
reverse 5’-ATG TCC GGT AAC GGC GGC-3’ 
TNF-α (amplicon size 174 bp) 
forward 5’-CAT CTT CTC AAA ATT CGA GTG ACA A-3’ 
reverse 5’-TGG GAG TAG ACA AGG TAC AAC CC-3’  
 
Table 2.3: List of PCR primers 
 
 
Conventional RT-PCR for semiquantitative analysis of gene expression was 
prepared and run as listed in Table 2.4. Aliquots of 10 µl for gel electrophoresis 
were taken after 28 and 30 cycles to ensure an analysis in the dynamic phase 
of the PCR reaction before reaching the plateau phase. Gels for electrophoresis 
were prepared with 1x TAE buffer and 1% Agarose (Gibco. Paisly, UK) + 0.5 
mg/ml ethidium bromide. TAE buffer was prepared as a 50x TAE stock (pH 8.0; 
for 1000 ml solution 242 g Tris base + 75.1 ml Glacial acetic acid + 37.2 g 
Na2EDTA + H20 to 1000 ml). Electrophoresis was run at a constant voltage of 
100 V for 60 min. PCR products were visualized under UV light and 
documented using a gel documentation system (PeqLab, Erlangen, Germany). 
The GeneRuler low range marker (Fermentas, Burlington, Ontario, Canada) 
served as marker for PCR product size. 
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Real-time RT-PCR for relative quantification of mRNA used PBGD (HMBS) and 
β-actin as the reference genes. Reactions were performed in an ABI 7700 
Sequence Detection System (Applied Biosystems, Foster City, CA). The 
composition of the reaction samples and the PCR conditions are listed in Table 
2.5. Additionally, agarose-gel analysis was performed to confirm the primary 
formation of a single specific PCR product. Fold-change in expression was 
determined (2-∆∆Ct method) as described in [119]. 
 
Total RNA     125 ng 
10x PCR buffer     2,5 µl 
dNTPs       10 mM 
MgCl2 50 mM     2 mM 
Forward primer     5 pM 
Reverse primer     5 pM 
Taq polymerase     2 U 
H2O (molecular biology grade)   to a final volume of 25 µl 
6min at 96°C, then 5 sec 95°C Æ 5 sec 60°C Æ 10sec 72°C 
for 30 cycles, then 4°C 
 
Table 2.4: RT-PCR reactions 
 
 
cDNA template (1 ng/µl)    5 ng 
Platinum® SYBR® Green qPCR SuperMix  10 µl   
MgCl2 50 mM      2 mM 
ROX Reference Dye 50x    0,5 µl  
Forward primer      45 pmol 
Reverse primer      45 pmol 
H2O (molecular biology grade)    to a final volume of 25 µl 
6min at 96°C, then 5 sec 95°C Æ 5 sec 60°C Æ 10sec 72°C 
for 40 cycles, then 4°C 
 
 
Table 2.5: qRT-PCR reactions 
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2.7  Statistics 
Data analysis and statistics were performed using Microsoft Excel Version 2000 
and SPSS Version 12.0. All data are displayed as mean values ± SD, unless 
otherwise noted. Statistical differences between treatment groups were 
estimated by Kruskal-Wallis test. If there were significant differences between 
the treatment groups (p < 0.05), further comparison of the groups was 
performed by Mann-Whitney U test. Differences were considered statistically 
significant when p values were < 0.05. 
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3  Results 
3.1  Identification and characterization of lung DC 
3.1.1 Flow cytometric characteriziation 
In normal mouse lung parenchymal tissue, two major populations of CD11c-
positive cells have been reported, including lung dendritic cells and lung 
macrophages. Using flow cytometry, these two populations can be 
distinguished by their autofluorescence properties in the FL1 channel, with lung 
DC displaying a low autofluorescence and lung Mφ a high autofluorescence 
[117]. Figure 3.1 shows a representative result of a lung preparation from an 
untreated mouse. 
 
 
Fig. 3.1: Flow cytometric identification of 
lung DC and lung Mφ 
CD11c-positive cells were isolated from 
lung homogenates using magnetic beads 
and analyzed by flow cytometry for their 
CD11c expression and their 
autofluorescence properties. 
 
 
As shown by others before, among the lung DC, two major subpopulations have 
been identified, including myeloid DC and plasmacytoid DC, of which the 
myeloid DC subset is the by far predominating DC population (>95%, [117]). 
Myeloid DC are characterized by their low autofluorescence and CD11bhigh, 
CD11chigh, MHCIIhigh and CD86mid-high and CD205low cell surface antigen 
expression profile. In contrast, plasmacytoid DC are CD11clow-mid, B220high but 
CD11bnegative. As opposed to lung DC, CD11c-positive lung macrophages have 
been shown to be highly autofluorescent, and to be MHCIIlow-mid, CD11bnegative, 
and CD86negative [56, 117]. 
Adopting these protocols, and to further characterize the two CD11c-positive 
populations in mouse lungs in the current study, CD11c-positive cells purified 
from lung homogenate of untreated mice were stained with a panel of 
monoclonal antibodies (Fig. 3.2). By this, CD11c-positive cells with low 
autofluorescent properties were identified to be mostly MHCIIhigh, CD205low, 
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CD11bhigh and CD86mid, thus representing myeloid dendritic cells with a mostly 
immature phenotype. Only a minor part of the lung DC showed a plasmacytoid 
phenotype. In untreated or vehicle-treated mice, the third DC population 
described in mice, the lymphoid DC subset (CD11chigh, CD11bnegative, CD8αhigh, 
B220negative), was not or only in very limited numbers detected in lung 
homogenates. FACS analysis of the highly autofluorescent CD11c-positive cells 
collected from lung homogenates revealed a CD11chigh, MHCIIlow, CD205negative-
low, CD11bnegative, CD86negative, F4/80positive immunophenotype, thus representing 
“classical” lung macrophages (Fig. 3.2). The monocyte-macrophage marker, 
F4/80, was expressed by both lung DC and lung Mφ. 
 
Fig. 3.2: Flow cytometric 
characteriziation of lung DC 
and lung Mφ 
CD11c-positive cells from lung 
homogenates were stained for 
CD11c and the indicated 
antigens. Gates for 
identification of DC and Mφ 
were set as displayed in Fig. 
3.1. Shaded histograms show 
the specific fluorescence for the 
indicated antigens; open 
histograms represent the 
respective unstained control. 
The data are representative of 
five independent experiments. 
 
 
3.1.2 Morphology of flow-sorted lung DC and Mφ 
Cytospin preparations of flow-sorted lung DC and lung Mφ were Pappenheim-
stained and examined by light microscopy. As depicted in figure 3.3 and in 
accordance to the literature [68, 117], lung DC displayed a monocytic 
phenotype, while lung Mφ displayed the typical morphology of alveolar Mφ. 
MHC II 
CD11b 
CD8α
B220
CD205CD86 
lung DC lung Mφ 
F4/80
lung DC lung Mφ
Fig. 3.3: Morphology of flow-sorted lung DC and lung Mφ 
Pappenheim-stained cytospins of flow-sorted lung DC and lung Mφ. Original magnification, x 40.
 
lung DC lung Mφ
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3.1.3 Stimulatory properties in an allogenic mixed lymphocyte 
reaction (MLR) 
 
To assess the role of lung DC to serve as antigen-presenting cells to naïve 
CD4-positive T cells in an allogenic MLR, flow-sorted lung DC, lung Mφ and 
lung PMN from C57BL/6 mice were incubated for 3 days with spleen CD4-
positive T cells from C3H/HEJ mice. After this, the number of viable cells in 
each well was assessed using a MTT test as outlined in 2.6.1. Although freshly 
isolated lung DC are mostly immature, thus displaying only a weak stimulatory 
potential in a MLR [68], they exhibited a stronger potential to induce T cell 
proliferation than lung Mφ and lung PMN (Figure 3.4). 
 
 
Fig. 3.4: Mixed lymphocyte reaction 
Flow-sorted lung DC, lung Mφ or lung PMN 
(20,000 cells per well) were co-incubated for 
3 days with 200,000 CD4-positive T cells. 
After 3 days, the number of living cells was 
assessed using the MTT test as described in 
Materials and Methods section. Background 
MTT absorption in blank wells was used as 
standard. MTT absorption in wells with DC, 
Mφ, or PMN was statistically compared to 
wells containing T cells only.  * signifies p < 
0.05 compared to T cells only. # signifies p < 
0.05 of DC compared to Mφ and PMN. 
 
 
 
3.2  Effect of systemic Flt3L application 
3.2.1  Effect of Flt3L application on the accumulation of lung DC 
Although systemic Flt3L application has been shown to expand the DC pool in 
various organs, including the lung, a time course of the Flt3L elicited lung DC 
accumulation has so far not been reported. Therefore, a time course analysis 
was undertaken. The identification of lung DC and lung Mφ was performed as 
described above. Figure 3.5 shows a representative direct comparison of the 
flow cytometric analysis of CD11c-positive cells from lung homogenates of a 
mouse treated systemically with Flt3L for nine consecutive days and a vehicle 
treated mouse that received PBS + 0.1% HAS only. 
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Fig. 3.5: Identification of lung DC and lung Mφ in lung 
homogenates from Flt3L- and vehicle-treated mice 
Identification of DC and Mφ in lung homogenates were 
performed as described in 3.1 (see also Fig. 3.1). 
 
 
 
 
 
As shown in Fig. 3.6, a significant increase in Flt3L-induced DC accumulation 
was noted in lung parenchymal tissue by day 5, with further increases observed 
on days 7 and 9 post-treatment. At day 9 of Flt3L treatment, numbers of lung 
DC were increased by a factor of ∼12 compared to controls, while numbers of 
lung Mφ were not altered in response to Flt3L treatment (Fig. 3.6). Of note, Flt3L 
application in mice also increased the numbers of neutrophils accumulating in 
lung parenchymal tissue with a peak observed by day 9 post-treatment (Fig. 
3.7). 
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Fig. 3.6: Time course of DC Flt3L-elicited lung DC
accumulation 
Mice were left untreated, or received a daily injection of
Flt3L for the indicated time intervals. Subsequently, CD11c-
positive cells from lungs were analyzed for their proportions
of low autofluorescent (DC) and high autofluorescent cells
(Mφ) (A). Absolute numbers of DC and Mφ in lungs were
calculated (B). Values in B show mean ± SD of 3-5 mice
per time point. * signifies p < 0.05 compared with control. 
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Fig. 3.7: Time course of Flt3L-elicited 
accumulation of PMN in mouse lungs 
In lungs obtained from mice treated 
systemically with Flt3L for the indicated time 
points, the percentage of PMN was 
analyzed by flow cytometry (high SSC, 
CD45high, GR-1high cells). Absolute PMN 
numbers in lung homogenates were 
calculated accordingly. Data are presented 
as mean ± SD of 3-5 mice per time point. * 
signifies p < 0.05 compared with control. 
 
 
 
Furthermore, the DC and Mφ obtained from lungs of Flt3L-treated mice were 
analyzed for their antigen expression profile as compared to the DC and Mφ 
from the lungs of vehicle-treated mice (Fig. 3.8, see also Fig. 3.2). Like for the 
total numbers in mouse lungs, Flt3L had no impact on the antigen expression of 
lung Mφ. In lung DC, the expression of MHC II and CD86 were comparable in 
both treatment groups, indicating that in both groups lung DC display an 
immature phenotype, which is in line with reports by others [68]. However, in 
response to Flt3L treatment, in addition to the myeloid DC subset which is 
dominating the lung DC pool in untreated and vehicle-treated mice, a small but 
detectable number of plasmacytoid DC (CD11clow-mid, CD11bneg, CD8αneg, 
B220pos) and lymphoid DC (CD11cpos, CD11bneg, CD8αpos, B220neg) was 
detected in lung homogenates.  
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Fig. 3.8: Phenotypic 
characterization of DC and Mφ 
obtained from lungs of vehicle- 
and Flt3L treated mice 
Lung DC and Mφ were identified as 
described and analyzed for the 
expression of the indicated 
antigens (see also legend to figure 
3.2). Shaded histograms represent 
the specific antigen expression, 
open histograms display control. 
The data are representative of five 
independent experiments. 
 
 
3.2.2 Time course of Flt3L-elicited DC accumulation in 
peripheral blood, spleen, and mediastinal lymph nodes 
As described by several others before [67, 70, 72, 78], also in the present study 
the subcutaneous application of Flt3L led to increased numbers of circulating 
blood monocytes starting already on day 3, thus preceeding the lung DC 
accumulation by approximately two days (Figure 3.9). In addition, DC 
accumulated in lung draining lymph nodes and the spleen with a similar time 
course as observed for the lung (Figure 3.10 and 3.11). 
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peripheral blood after systemic Flt3L
treatment 
Mice were treated with a daily injection of
10 µg Flt3L. At the indicated time points,
mice were killed, and blood smears were
prepared. Differential cell counts were
done on Pappenheim-stained blood
smears by counting 100 cells per mouse.
Data are displayed of mean ± SD of 3-5
mice per time point. * signifies p < 0.05
compared with control. 
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Fig. 3.10: DC in spleens after Flt3L 
treatment 
At the indicated time points of systemic 
Flt3L treatment, spleen homogenates were 
prepared and analyzed by flow cytometry. 
Spleen DC were identified as CD11cpositive 
MHC IIhigh cells.  
* signifies p < 0.05 compared with control. 
 
 
 
 
 
Fig. 3.11: DC in mediastinal lymph 
nodes after Flt3L treatment 
At the indicated time points of systemic 
Flt3L treatment, homogenates of 
mediastinal lymph nodes were prepared 
and analyzed by flow cytometry. Lymph 
node DC were identified as CD11cpositive 
MHC IIhigh cells. * signifies p < 0.05 
compared with control. 
 
 
 
3.3 Expression patterns of adhesion molecules 
The fact that systemic Flt3L treatment elicits both DC and PMN accumulation in 
the lung raises the necessitity to differentiate between the role of Flt3L elicited 
lung DC versus co-recruited PMN during the acute inflammatory responses of 
the lung. In other words, the role of Flt3L elicited lung DC has to be carefully 
elaborated from the global impact of Flt3L treatment on acute lung 
inflammation. 
A possible approach to discriminate between these two overlapping effects of 
Flt3L is the selective inhibition of Flt3L elicited DC recruitment to the lung by the 
use of function-blocking mAbs to cellular adhesion molecules. As a first step to 
this and to identify possible target molecules in Flt3L treated mice, a panel of 
mAbs was used to characterize the expression of different adhesion molecules 
on circulating peripheral blood monocytes (PBMo), circulating DC and PMN in 
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peripheral blood, lung DC, and lung Mφ. The panel of mAbs comprised: Two of 
the α integrins that dimerize with the β1 integrin chain and have been 
demonstrated to be the most important for the recruitment of monocytoid cells in 
the mouse, α4 integrin/VLA-4 and α5 integrin/VLA-5 (CD49d and CD49e, 
respectively) [120, 121];  the β2 integrin (CD18) and its dimerization partners αL 
integrin (CD11a) and αM integrin (CD11b); and the selectins primarily involved 
in monocyte recruitment in the mouse, L-selectin (CD62L) and the receptor for 
P-selectin, PSGL-1 (CD162).  
As shown in Fig. 3.12, monocytes, circulating DC and PMN in mouse blood 
expressed all β2 integrins, while the expression of β1 integrins was restricted to 
monocytes and  DC. Expression of CD62L was restricted to a subset of both 
PBMo and DC, but could not be attributed to a specific subset, like the GR-1-
positive or -negative PBMo or the CD11b-positive or –negative DC.  
After recruitment to the lung, DC did not change the expression of the analyzed 
antigens. Lung Mφ, however, showed a different expression profile, as 
compared to circulating monocytes, with the absence of CD11b, CD49d, 
CD62L, and CD162. 
Data presented in Fig. 3.12 represent adhesion molecule expression patterns 
after nine days of systemic Flt3L treatment. This expression profile was not 
different from the expression profile in vehicle-treated or untreated mice (data 
not shown). 
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Fig 3.12: Expression profiles of adhesion molecules 
Mice were treated for nine consecutive days with Flt3L, and peripheral blood monocytes 
(PBMo), peripheral blood DC (PBDC), blood neutrophils (PMN), lung DC, and alveolar 
macrophages (lung Mφ) were analyzed for the expression of the indicated ahesion molecules. 
Cell populations were identified by appropiate gating as indicated. Open histograms indicate the 
unstained cells, shaded histograms show the specific fluorescence. Results are representative 
of five independent experiments. 
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3.4.  Blockade of Flt3L elicited DC recruitment to the lung by 
monoclonal antibodies against adhesion molecules 
The next step in identifying possible target adhesion molecules was the 
application of function-blocking mAb in order to analyze the molecular pathways 
mediating the Flt3L elicited lung DC but not PMN accumulation, thus 
establishing a system to differentiate the role of Flt3L elicited lung DC versus 
co-recruited neutrophils in the lung’s inflammatory response to bacterial LPS. 
Therefore, mice were treated for nine consecutive days with Flt3L. Additionally, 
mice received intraperitoneal injections of function-blocking mAb or matching 
isotype control antibodies on days 1, 3, 5, 7, and 9 of Flt3L treatment. On day 
10, mice were sacrificed and subjected to analysis. 
As shown in Fig. 3.13, application of function-blocking mAb with specificity for 
the β2 integrins CD11a, CD11b or the common β2 chain CD18 significantly 
blocked the Flt3L elicited lung DC accumulation by >70% compared to controls. 
In marked contrast, blockade of the β1 integrin CD49d (VLA-4) or its receptor 
CD106 (VCAM-1) did not reduce the Flt3L elicited lung DC accumulation. Also, 
blockade of the β2 integrin receptor CD54 (ICAM-1) only slightly reduced 
numbers of lung DC in the lung parenchyma of Flt3L treated mice, implying that 
lung DC accumulation in response to Flt3L utilizes alternative adhesion 
pathways independent of ICAM-1. In addition, blockade of JAM-c, a junctional 
adhesion molecule localized at lung endothelial and epithelial tight junctions 
[122] slightly but non-significantly blocked the Flt3L-elicited lung DC 
accumulation. These data show that Flt3L elicited lung DC accumulation largely 
depends on engagement of β2 but not β1 integrins or JAM-c.  
 
Fig. 3.13: Analysis of the adhesion 
molecules mediating Flt3L elicited 
accumulation of lung DC 
Mice were treated for 9 consecutive days 
with Flt3L and function-blocking mAb to the 
indicated adhesion molecules. On day 10, 
number of lung DC was analyzed as 
outlined above. Values are presented as 
mean ± SD of 3-5 mice per treatment 
group. $ signifies p < 0.05 as compared 
with Flt3L-treated isotype control group. 
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This conclusion is also supported by an immunohistochemistry analysis as 
presented in Fig. 3.14, showing that the Flt3L induced accumulation of 
CD11cpositive/CD11bpositive lung DC within the lung interstitial compartment was 
nearly completely blocked in Flt3L-treated mice co-treated with anti-CD11a 
mAb. At the same time, numbers of resident alveolar macrophages located 
within the alveolar air space (CD11cpositive,F4/80positive, CD11bnegative) remained 
unaffected.  
 
Fig. 3.14: Effect of β2 integrin blockade on the accumulation of CD11c-positive cells 
in the lungs of Flt3L treated mice.  
Mice were either injected with vehicle (A-D) or Flt3L for nine days (10 µg/mouse/day) (E-L) 
in the presence of either isotype control (A-H) or function-blocking anti-CD11a mAb (I-L). 
Subsequently, mice were killed and immunohistochemistry was performed on lung 
crysections stained with anti-CD11c mAb (B,F,J), anti-CD11b mAb (C,G,K), anti-F4/80 mAb 
(D,H,L), or control Ab (A,E,I), as indicated. Note that in anti-CD11a mAb pretreated mice, 
numbers of intra-alveolar CD11c-/F4/80-positive, CD11b-negative cells representing 
alveolar macrophages (arrows) remained unchanged, while Flt3L elicited CD11c-/CD11b-
positive cells accumulating in the lung interstitial compartment (lung DC) were strongly 
reduced. Original magnification, x20. 
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The analysis of DC in spleens and mediastinal lymph nodes of the mice co-
treated with Flt3L and function-blocking antibodies showed that, in marked 
contrast to the findings in lung DC recruitment, Flt3L-elicited DC recruitment to 
these organs was not blocked by any of the function-blocking mAb applied in 
this study (Fig. 3.15). This indicates that the blocking effect of anti-β2 integrin 
mAb on lung DC accumulation is due to a specific blockade of DC migration to 
the lung as opposed to a possibly occurring antibody-mediated depletion of 
precursor cells in peripheral blood. Also, proportions of myeloid, lymphoid and 
plasmacytoid DC subsets were not significantly affected in lungs, mediastinal 
lymph nodes or spleens in mice pretreated with Flt3L in the absence or 
presence of blocking antibodies (data not shown).  
 
 
 
Fig. 3.15: DC in spleens and 
mediastianal lymph nodes in mice 
treated with Flt3L ± function-blocking 
mAb 
Mice were treated as described in Fig. 3.13. 
On day 10, spleens and mediastianal lymph 
nodes were harvested, and percentages of 
DC (CD11cpositive, MHC IIhigh) were analyzed 
by flow cytometry. Values are presented as 
mean ± SD of 3-5 mice per treatment 
group. * signifies p < 0.05 compared with 
vehicle-treated mice. isotp, isotype control 
IgG. 
 
 
 
3.5 Effect of Flt3L induced lung DC accumulation on the lung 
inflammatory response to LPS 
3.5.1  Cells in lung homogenate 
To evaluate the role of lung DC in LPS-induced lung inflammation, mice were 
either left untreated or were pretreated with LPS for 24h or were pretreated with 
Flt3L for nine days to increase numbers of lung DC within the lung parenchymal 
tissue followed by intratracheal application of LPS for 24h. As shown in Fig. 
3.16, LPS application in the absence of Flt3L pretreatment only slightly 
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increased numbers of lung DC in lung parenchymal tissue, whereas Flt3L 
application alone significantly increased numbers of lung DC. However, 
application of LPS into the lungs of Flt3L pretreated mice further increased 
numbers of DC in lung parenchymal tissue approximately four-fold over lung DC 
numbers observed in the lungs of Flt3L only treated mice. This indicates that 
Flt3L plus LPS treatment of mice synergistically enhanced the lung DC 
accumulation compared to either treatment regimen alone. This synergistic 
action of Flt3L and LPS to elicit a drastic increase in lung DC numbers was 
strongly and significantly reduced in the presence of anti-CD11a but not anti-
CD49d blocking antibodies, again demonstrating that acute inflammatory lung 
DC accumulation in response to Flt3L plus LPS was critically dependent on 
engagement of β2 integrins but not β1 integrins (Fig. 3.16). In addition, the 
observed co-recruitment of neutrophils into the lung parenchymal tissue of Flt3L 
treated mice was also further increased in mice challenged with Flt3L plus LPS 
(Fig. 3.16). In striking contrast to the inflammatory lung DC accumulation, 
neutrophil recruitment did not depend on engagement of CD11a or CD49d, 
corresponding to previously published results [121]. Collectively, these data 
show that both the lung DC and neutrophil accumulation is strongly increased in 
mice co-treated with Flt3L in the presence of intratracheal LPS, and blockade of 
CD11a selectively and significantly attenuates the inflammatory lung DC but not 
lung neutrophil recruitment. Thus, anti-CD11a blocking antibody application is 
an effective tool to dissect the effects of Flt3L elicited lung DC versus lung 
neutrophils on the lung inflammatory response to endotoxin challenge. 
To further differentiate the contribution of Flt3L elicited lung DC versus 
neutrophils on LPS induced lung inflammation, both Flt3L- and vehicle-
pretreated mice were concomitantly depleted of circulating neutrophils via 
systemic application of anti-GR-1 mAb. This treatment regimen has been shown 
recently to deplete circulating neutrophils but not Gr-1 positive monocyte 
subsets in peripheral blood [116]. Importantly, transient neutropenia induced in 
Flt3L plus LPS and LPS only treated mice efficiently depleted lung neutrophils 
without affecting numbers of lung DC (Fig. 3.16). 
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Fig. 3.16: Numbers of DC and PMN in 
lungs in response to intratracheal LPS 
application 
Mice were treated as described above, 
and numbers of DC and PMN in lungs 
were analyzed by flow cytometry as 
desribed. Values are presented as mean 
± SD of 4 mice per group.  
* signifies p< 0.05 compared to vehicle-
treated mice; $ signifies  p < 0.05 
compared to Flt3L only treated mice. #  
signifies p < 0.05  compared to LPS only 
treated mice. itp, isotype control IgG 
 
 
3.5.2  Cells in BAL fluid 
The analysis of BAL fluid cellular constituents from mice of the various 
treatment groups showed that LPS treatment alone elicited a ~5 fold increase in 
total BAL cell numbers (Fig. 3.17), attributable to a moderate neutrophilic 
alveolitis with low numbers of co-recruited alveolar DC in the absence of 
lymphocytes (Fig. 3.18 A and B), which is in line with previously published 
results [118, 123, 124]. Of note, Flt3L treatment alone did neither induce an 
increase in total BAL cells nor an alveolar accumulation of neutrophils or an 
alveolar DC or lymphocyte recruitment (Fig. 3.17, 3.18 A and B). In striking 
contrast, Flt3L-pretreated mice challenged with LPS for 24h developed a 
significantly increased neutrophilic alveolitis compared to mice challenged with 
LPS alone and recruited significantly more DC into the alveolar air space (200-
300 fold above control) than induced by either treatment regimen alone (Fig. 
3.18 A and B). Anti-CD11a mAb but not anti-CD49d mAb application in Flt3L 
pretreated mice significantly attenuated the alveolar DC recruitment in response 
to LPS and also reduced the numbers of alveolar recruited neutrophils (Fig. 
3.17 A), which was not observed for the lung interstitial compartment (Fig. 
3.16), implying that the β2 integrin CD11a is critical to lung parenchymal and 
alveolar recruitment of both lung and alveolar DC, whereas CD11a appears to 
be more relevant for the neutrophil recruitment across the alveolar epithelial as 
opposed to the capillary endothelial barrier. 
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Fig. 3.17: Total BAL cells in response 
to intratracheal LPS application 
Mice were treated as described above, 
and lungs were lavaged on day 10 (= 24h 
after intratracheal LPS application). Cells 
in BAL fluid were counted with a 
Neubauer chamber. Values are 
presented as mean ± SD of 4 mice per 
group.  
* signifies p< 0.05 compared to vehicle-
treated mice; #  signifies p < 0.05  
compared to LPS only treated mice. itp, 
isotype control IgG 
 
 
3.5.3  Proinflammatory cytokines in BAL fluid 
The proinflammatory mediator release and lung barrier dysfunction in mice of 
the various treatment groups was also assessed. LPS challenge but not Flt3L 
pre-treatment of mice elicited a weak alveolar liberation of TNF-α and IL-12 
(Fig. 3.19). In contrast, Flt3L pretreated and LPS challenged mice responded 
with strongly increased BAL fluid TNF-α levels (Fig. 3.19 A) and excessive IL-12 
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Fig. 3.18: Differential cell counts in BAL fluid 
Cells in BAL were differentiated by differential cell counts on Pappenheim-stained cytospins as
well as by flow cytometry into rAM and PMN (A) and DC and Lymphocytes (B), respectively.
Note that the number of resident alveolar macrophages (rAM) did not change significantly by
any treatment. Values are presented as mean ± SD of 4 mice per group.  
* signifies p< 0.05 compared to vehicle-treated mice; #  signifies p < 0.05  compared to LPS
only treated mice. itp, isotype control IgG. Lymph, lymphocyte. 
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levels in BAL fluid (Fig. 3.19 B). This effect could be nearly completely 
abrogated by pre-treatment of the mice with anti-CD11a but not anti-CD49d 
blocking antibodies. In contrast, induction of transient neutropenia in mice 
pretreated with Flt3L plus LPS only weakly attenuated BAL fluid TNF-α and IL-
12 levels.  
 
Fig. 3.19: Proinflammatory cytokines in BAL fluid 
BAL fluid concentrations of TNF-α (A) and IL-12 (B) were measured by ELISA. Values are 
presented as mean ± SD of 4 mice per group. * signifies p< 0.05 compared to vehicle-treated 
mice; #  signifies p < 0.05  compared to LPS only treated mice. itp, isotype control IgG. 
 
 
3.5.4 Assessment of lung leakage 
Furthermore, in order to characterize the inflammatory phenotype upon 
intratracheal LPS application, the function of the lung barrier was assessed by 
different approaches to measure an increased leakage to the alveolar space. 
Firstly, total protein in BAL fluid was measured using a Bradford assay (Fig. 
3.20). Secondly, BAL fluid from the various treatment groups was subjected to 
gel electrophoresis, and the intensity of the 66 kDa band representing mouse 
serum albumine was quantified and compared to the vehicle-treated, non-
inflamed control (Fig. 3.21 A and B). Finally, the lung leakage after intratracheal 
LPS instillation was assessed using the leakage of intravenously administered 
FITC-labeled albumin into the alveolar space (Fig. 3.22). 
A 
600 
1000 
800 
1200 
400 
200 
0 
TN
F-
α i
n 
B
A
LF
 (p
g/
m
l) #
# 
* 
*
* 
* 
*
*
Flt3L s.c. - - + + -
mAb i.p. 11a 49d itp itp GR-1
LPS i.t. + - 
+ 
itp 
- ++ + 
+
itp
+
+
GR-1
+
0
10,000
20,000
30,000
40,000
50,000
60,000
IL
-1
2 
in
 B
A
LF
 (p
g/
m
l) 
Flt3L s.c. - - + + -
mAb i.p. 11a 49d itpitp GR-1
LPS i.t. +-
+
itp
- ++ + 
+ 
itp 
+ 
+
GR-1
+
*
* 
* 
*
# 
# 
#
* 
*
B
3  Results 46
As shown in Figures 3.20-3.22, intratracheal LPS challenge but not Flt3L pre-
treatment of mice elicited a moderate increase in lung permeability. However, 
the intratracheal instillation of LPS to mice that had been pretreated with Flt3L 
resulted in a strongly and significantly increased lung permeability. As for the 
proinflammatory cytokines in BAL fluid, the induction of transient neutropenia in 
mice pretreated with Flt3L plus LPS had no effect on the lung permeability in 
these mice. 
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3.21: SDS-PAGE of BAL fluids 
(A) BAL fluid samples were subjected to SDS-
PAGE as described in Materials and Methods 
section (see 2.5.6). The 66 kDa band was 
identified as mouse serum albumin by MALDI-
TOF analysis (Patrick Bulau, personal 
communication).  
(B) The intensity of the albumin band was quantified densitometrically. Relative densities were 
calculated compared with the vehicle-treated, not LPS-challenged treatment group. Values are 
presented as mean ± SD of 4 mice per group. * signifies p< 0.05 compared to vehicle-treated mice; #  
signifies p < 0.05  compared to LPS only treated mice. itp, isotype control IgG. 
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3.20: Total protein content in BAL fluid 
Total protein in BAL fluid was measured by
Bradford protein assay. Values are
presented as mean ± SD of 4 mice per
group.  
* signifies p< 0.05 compared to vehicle-
treated mice; #  signifies p < 0.05
compared to LPS only treated mice. itp,
isotype control IgG. 
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Fig. 3.22: FITC albumin leakage after 
intratracheal LPS instillation 
For assessment of lung leakage, mice 
were injected intravenously with 1 mg of 
FITC-labeled albumin one hour before 
analysis. FITC fluorescence in serum and 
BAL fluid was measured, and ratios were 
calculated (see also 2.5.7). Values are 
presented as mean ± SD of 4 mice per 
group. * signifies p< 0.05 compared to 
vehicle-treated mice; #  signifies p < 0.05  
compared to LPS only treated mice. itp, 
isotype control IgG. 
 
 
 
Collectively, these data show that LPS challenge of Flt3L pretreated mice 
significantly aggravates the lung inflammatory response, as reflected by 
strongly increased lung parenchymal and alveolar DC and neutrophil numbers, 
as well as in significantly increased BAL fluid TNF-α, IL-12, and serum protein 
levels. Importantly, selective inhibition of Flt3L elicited lung parenchymal and 
alveolar DC accumulation significantly attenuated both the LPS induced 
cytokine release and lung permeability changes, whereas transient neutropenia 
did not significantly attenuate the increased lung permeability observed in Flt3L 
pretreated plus LPS challenged mice. 
 
3.6  Klebsiella pneumoniae infection in Flt3L pretreated mice 
To investigate whether the Flt3L-mediated amplification of the inflammatory 
response to LPS also occurred in a model of Gram-negative pneumonia, mice 
were pretreated for nine days with Flt3L or vehicle, followed by intratracheal 
instillation of 104 CFU K. pneumoniae as described in Materials and Methods 
section (see 2.4.3). At 24 h, 48 h, and 96 h post-infection, mice were analyzed 
of the developing lung inflammatory response, as described for the analysis of 
mice after intratracheal LPS instillation. Infection of vehicle-treated mice with 
104 CFU K. pneumoniae caused a marked inflammation comparable to the 
changes observed in mice in response to LPS instillation. Similar to the findings 
made in LPS-challenged mice, Flt3L pretreated mice were found to exhibit 
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increased total BAL fluid cell numbers compared to vehicle-treated mice, 
attributable to a modest increase in PMN numbers and a strong increase in BAL 
DC numbers (Fig. 3.23 A-C). This was accompanied by a slight, but not 
significant increase in BAL TNF-α levels (Fig. 3.24 A) and a strong increase in 
BAL fluid IL-12 levels (Fig. 3.24 B). Similar to the LPS model, Flt3L pre-
treatment also led to an increased lung permeability as assessed by total BAL 
protein content and i.v. FITC albumin leakage into the alveolar air space (Fig. 
3.25). Moreover, and most importantly, Flt3L pre-treatment of mice also led to 
an increased mortality upon infection of the mice with K. pneumoniae, whereas 
K. pneumoniae-infected vehicle-treated mice were able to control the infection 
(Fig 3.26). 
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Fig. 3.23: BAL fluid cells after K. pneumoniae
infection 
At the indicated time points after intratracheal
infection with 104 CFU K. pneumoniae, cells in BAL
fluid were analyzed as described above for total cell
numbers (A), alveolar DC (B), and alveolar PMN
(C) by differential cell counts of Pappenheim-
stained cytospins and flow cytometry. Values are
presented as mean ± SD of 4-6 mice per group.   
# indicates p < 0.05 as compared  with K.
pneumoniae-infected, vehicle-treated mice. 
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Fig. 3.24: Proinflammatory cytokines in BAL fluid after K. pneumoniae infection 
Mice were treated as described above. Levels of TNF-α (A) and IL-12 (B) were measured with 
ELISA. Values are presented as mean ± SD of 4-6 mice per group. # indicates p < 0.05 as 
compared  with K. pneumoniae-infected, vehicle-treated mice. 
 
 
 
 
Fig. 3.25: Total protein in BAL fluid and FITC albumin leakage after K. pneumoniae 
infection 
Lung leakage was assessed as described above for the mice after intratracheal LPS instillation. 
Total protein in BAL fluid (A) and FITC albumin leakage (B) were determined as described. 
Values are presented as mean ± SD of 4-6 mice per group. # indicates p < 0.05 as compared  
with K. pneumoniae-infected, vehicle-treated mice. 
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Fig. 3.26: Survival after intratracheal 
infection with K. pneumoniae 
Mice were pretreated with Flt3L or vehicle 
as described. On day 9, mice were 
infected intratracheally, and survival was 
monitored for 96 h after infection (n = 6 
mice per group). 
 
 
 
3.7  LPS-induced peritonitis in Flt3L pretreated mice 
To analyze whether the observed amplification of lung inflammatory responses 
in Flt3L-pretreated mice is a lung-specific phenomenon or might also develop in 
other organ systems, both Flt3L- and vehicle-treated mice were challenged with 
an intraperitoneal injection of 20 µg ultrapure LPS. Peritoneal lavage for the 
analysis of differential cell counts and flow cytometric identification of peritoneal 
DC was performed 24h later. As shown in Fig. 3.27, Flt3L pre-treatment led to a 
strong and significant increase in peritoneal DC by a factor of ~15 and a slight 
but significant increase in neutrophil counts. In both Flt3L- and vehicle-treated 
mice, intraperitoneal LPS injection induced a significant increase in neutrophil 
numbers. However, in marked contrast to the observations made in the lung, 
Flt3L pre-treatment did not provoke increased numbers of DC or PMN 
accumulating in the peritoneal cavity upon intraperitoneal LPS application. 
 
Fig. 3.27: Cells in peritoneal lavage 
after Flt3L and/or LPS injection 
Mice were pretreated with Flt3L or vehicle 
for nine consecutive days, as indicated. 
On day 9, mice received an intraperitoneal 
injection of 20 µg ultrapure LPS, and were 
analyzed 24h later. Cells in peritoneal 
lavage fluid were analyzed using 
Pappenheim-stained cytospins and flow 
cytometry. Values are presented as mean 
± SD of n=4 animals per group. * signifies 
p < 0.05 compared to vehicle-treated 
mice; # signifies p < 0.05  compared to 
LPS only treated mice. i.p., 
intraperitoneal. 
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3.8   Expression of proinflammatory cytokines by lung DC 
3.8.1  In vivo expression of proinflammatory cytokines in lung 
DC after LPS instillation 
To assess whether lung DC following in vivo exposure to bacterial toxins 
respond with proinflammatory cytokine release, mice received an intratracheal 
application of either LPS (1 µg/mouse) or sterile saline. Six hours later, flow-
sorted lung DC were analyzed for TNF-α and macrophage inflammatory 
protein-2 (MIP-2) mRNA transcripts using RT-PCR. Lung DC strongly 
upregulated TNF-α and MIP-2 mRNA levels as compared to untreated mice, 
demonstrating their active participation in mediator production upon intra-
alveolar LPS deposition. As a positive control, the induction of TNF-α and MIP-2 
expression in resident alveolar Mφ was also assessed; these cells are known to 
be major producers of these cytokines after intratracheal LPS instillation [125]. 
As shown in Fig. 3.28, both lung DC and Mφ upregulated TNF-α mRNA. Lung 
DC upregulated also mRNA for MIP-2, while MIP-2 mRNA transcripts in lung 
Mφ were already present in Mφ from control mice. This is probably due to an 
activation of these highly sensitive cells by the flow sorting procedure. 
 
 
 
Fig. 3.28: Expression of TNF-α and MIP-2 mRNA in 
lung DC and lung Mφ after intratracheal LPS 
instillation 
Mice were instilled with either 1 µg LPS or sterile saline, 
as indicated. 6 h later, mice were killed, and DC and Mφ 
were sorted from lung homogenates. After mRNA 
isolation, expression of TNF-α and MIP-2 were assessed 
with RT-PCR. β-Actin served as loading control. Gels are 
representative of 3 independent experiments.  
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3.8.2   Effect of Flt3L on LPS-induced cytokine gene expression 
in lung DC  
In addition to the inducibility of proinflammatory cytokines in lung DC and lung 
Mφ in vivo, we also questioned whether Flt3L application in mice affects the 
ability of lung DC to respond to LPS treatment with increased cytokine TNF-α, 
MIP-2, and IL-12 p35 mRNA levels. Flow-sorted lung DC from vehicle-treated or 
Flt3L pretreated mice were stimulated with 100 ng/ml LPS for 6h in vitro, 
followed by quantitative RT-PCR (qRT-PCR) analysis of TNF-α, MIP-2, and IL-
12 p35 mRNA levels. As shown in Fig. 3.29, no significant differences in TNF-α 
and MIP-2 mRNA levels were noted in LPS-stimulated lung DC of vehicle-
treated versus FLt3L pretreated mice, while the expression of IL-12 p35 was 
significantly upregulated in lung DC from Flt3L pretreated mice. This finding 
suggests that Flt3L application in vivo differentially affects the inflammatory 
response of lung DC to LPS treatment with an increased capability to produce 
the proinflammatory cytokine IL-12, while the increase in TNF-α in BAL fluid of 
Flt3L-pretreated mice after LPS instillation is most probable due to the Flt3L-
elicited increase in total numbers of lung parenchymal and alveolar 
accumulating DC. 
 
Fig. 3.29: Induction of proinflammatory 
cytokine expression in DC from Flt3 and 
vehicle-treated mice 
Lung DC from Flt3L and vehicle-treated 
mice were flow sorted and stimulated in 
vitro for 6 h with LPS or medium alone. 
mRNA transcript levels of the indicated 
cytokines were analyzed using qRT-PCR. 
Data are displayed as fold-change of 
mRNA levels in LPS-stimulated DC as 
compared with unstimulated DC. Values 
are presented as mean ± SD of 3 
independent experiments. * indicates p < 
0.05 as compared with vehicle-treated 
mice.   TNF- MIP-2
lung DC (Flt3L treated mice)
lung DC (control mice) 
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4  Discussion 
In the present study, the hypothesis was tested that lung dendritic cells, beside 
their well-known role as antigen-presenting cells, might also sample and 
respond acutely to inhaled bacterial toxins and thus contribute to the regulation 
of acute lung inflammatory responses to inhaled bacterial pathogens. Since 
there is no reliable system available to deplete DC selectively from mouse lungs 
without interfering with the lung macrophage pool or other immune cells (see 
also 1.2), a model of lung DC enrichment and selective inhibition of DC 
enrichment had to be employed. Of note, Flt3L does not only enrich DC, but 
also other cells of the immune system, with the most important for innate 
immune responses being PMN [66, 68]. Therefore, a strategy of selective 
blockade and/or depletion of Flt3L elicited lung DC and lung PMN had to be 
established and employed. 
The analysis of adhesion molecules mediating the enrichment of lung DC in 
response to systemic Flt3L treatment demonstrated that blockade of the β2 
integrin CD11a but not the β1 integrin CD49d inhibited the Flt3L elicited lung DC 
accumulation without interfering with the lung neutrophil recruitment. Induction 
of transient neutropenia by application of anti-GR-1 mAb depleted both 
circulating neutrophils and Flt3L elicited lung neutrophils without interfering with 
the Flt3L elicited lung DC pool size. Importantly, Flt3L pretreated mice 
responded with both significantly higher lung and alveolar DC and neutrophil 
numbers upon intratracheal LPS challenge than either Flt3L or LPS alone 
treated mice, and this effect was accompanied by a highly elevated BAL fluid 
proinflammatory mediator release and a significantly increased lung 
permeability. Of note, antibody-mediated blockade of lung DC accumulation but 
not transient neutropenia decreased the LPS-induced lung permeability and 
mediator release to baseline levels, demonstrating a yet unrecognized role of 
lung DC in regulating lung barrier integrity. Such DC-dependently amplified lung 
inflammatory response to LPS was also observed in mice challenged 
intratracheally with Klebsiella pneumoniae. In addition, Flt3L pretreated mice 
infected with K. pneumoniae showed an increased mortality compared to 
vehicle-treated and K. pneumoniae-infected mice. These data demonstrate that 
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in the lung, DC may act as critical regulators of the lung inflammatory response 
to inhaled bacterial pathogens. 
 
4.1  Identification and characterization of lung DC 
In mice, the major surface antigen expressed by DC which is used for 
identification is the αx integrin chain (CD11c). However, this marker is not 
restricted to DC, but other cell types also express this marker in different 
amounts, such as subsets of NK cells [126] and some microglia cells [127, 128]. 
Most importantly for the lung, also alveolar macrophages express high levels of 
CD11c [21, 56, 117, 129]. At present, no DC-specific marker has been 
described in the mouse system. For example, the murine homologues of the 
human DC-specific marker, DC-SIGN, are also expressed in different amounts 
in multiple other cells [130-132]. Thus, the flow cytometric characterization of 
mouse dendritic cells requires a combination of different markers. Recently, 
Vermaelen and Pauwels have described a method to discriminate lung DC and 
Mφ on the basis of CD11c expression and autofluorescence, with DC displaying 
a low and Mφ a high autofluorescence [56, 117]. Other authors have reported 
different protocols for lung DC isolation, mostly including a density gradient 
centrifugation step and/or a plastic adhesion to remove lung Mφ [68, 133, 134]. 
These steps are not only laborious and yield relatively low numbers of lung DC, 
but they also affect lung DC maturation status and surface marker expression 
patterns. Instead, DC isolated directly using a fast positive selection strategy 
most probably reflect the typical lung DC best [134]. 
Therefore, the protocol based on magnetic bead isolation of CD11cpositive cells 
from lung homogenates, followed by flow cytometric detection of CD11c 
expression and autofluorescence, was adopted for the current study. In line with 
the results shown by Vermalen and Pauwels, this approach yielded consistent 
numbers of lung DC and Mφ that could be both analyzed for surface antigen 
expression and flow-sorted for mRNA isolation and in vitro stimulation 
experiments. Five-colour flow cytometric analysis confirmed the typical antigen 
expression profiles of the two cell populations (see 3.1.1). Most importantly, 
lung DC co-expressed high levels of MHC II and low levels of CD86, thus 
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representing immature DC. Flow-sorted low and high autofluorescent, 
CD11cpositve cells displayed the typical morphology of immature DC and lung 
Mφ, respectively (see 3.1.2). Moreover, the high lymphocyte stimulatory 
capacity of lung DC as compared to lung Mφ and lung PMN could be confirmed 
in an allogenic mixed lymphocyte reaction (see 3.1.3). Hence, the approach 
was confirmed to provide a reliable and stable isolation and analysis of lung DC. 
In other organs, DC were identified in flow cytometry by their CD11cpositive MHC 
IIhigh phenotype, an approach that has been established by many researchers 
over the past decades. 
 
4.2  Treatment with Flt3L 
Treatment with Flt3L to increase DC numbers in various organs, including the 
lung, is a well characterized model and has been described by a large body of 
literature. In almost all of these studies, recombinant human Flt3L has been 
used, which has been shown to work effectively also in mice [28, 66-68, 75, 76, 
79, 134]. This is probably due to the high homology of human and mouse forms 
of Flt3L, which is 72% [70]. One study using an adenoviral vector to 
overexpress murine Flt3L in mice in vivo showed comparable effects on DC 
expansion, but demonstrated some differences in tumor control when compared 
to a treatment with human Flt3L [135]. However, since recombinant human 
Flt3L is the best characterized substance and already has some proposed 
therapeutic intervention applications [70], human Flt3L was chosen for the 
current study. The reported administration routes for systemic treatment are 
either subcutaneous or intraperitoneal. Both routes seem to work equally well. 
In the current study, in order to minimize the risk of peritoneal infection, the 
subcutaneous route was chosen. 
Most authors have used a systemic application for Flt3L treatment. However, in 
rats a single intratracheal dose of Flt3L has been shown to increase functional 
lung and BAL DC numbers [69]. In preliminary experiments, it was attempted to 
reproduce these findings in mice. In contrast to the findings in rats, no 
significant increase of DC numbers in lung homogenate or BAL could be 
detected after the intratracheal instillation of 50 µg Flt3L. Except a ~2fold 
increase in DC numbers in the mediastinal lymph nodes, no systemic effect was 
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noted (results are not shown in detail). Therefore, the systemic application 
model was chosen. 
Up to present, no time course for Flt3L elicited lung DC accumulation has been 
reported in the literature. Most authors, and all studies that have investigated 
Flt3L effects in the lung, have reported a treatment for nine consecutive days; 
single studies have used a treatment time of 5 days [78], 6 days in neonatal 
mice [77], and both 9 and 11 days [67]. Hence,  in order to define a time point 
with optimal DC accumulation in the lung with a minimal treatment time, a time 
course was undertaken. It turned out that a treatment for 9 consecutive days 
indeed revealed the best and most reliable increase in lung DC numbers (see 
Fig. 3.6); therefore, for the following experiments a treatment time of 9 days was 
chosen. 
As reported by others before, systemic treatment with Flt3L did not only 
increase the numbers of mainly myeloid DC, but also significantly the number of 
PMN, a central cell in early immune responses and innate immunity, in the 
blood and in lung homogenate [66, 68]. Thus, to decipher the role of DC in 
acute lung inflammation, a strategy had to be developed to distinguish the effect 
of Flt3L treatment (which increases both DC and PMN numbers) and the effect 
of Flt3L elicited lung DC. For PMN, a simple, effective and specific depletion 
strategy by injection of anti-GR-1 mAb has been described that does not affect 
the GR-1positive subset of monocytes in the peripheral blood [116]. Since a 
selective depletion system for lung DC is not available, a selective inhibition of  
lung DC recruitment after Flt3L treatment was adressed using monoclonal 
antibodies. 
 
4.3  Adhesion molecules and recruitment of lung DC 
As a first step to an intervention strategy with mAbs that target cellular adhesion 
molecule interaction, circulating PBMo, DC and PMN as well as lung DC and 
lung Mφ where phenotyped by flow cytometry for their expression of various 
adhesion molecules (see Fig. 3.12). The panel was chosen according to 
previously published results showing that integrins and selectins play the most 
important role in recruitment of monocytes and PMN to various organs 
(reviewed in [88, 120]). The expression profiles (see Fig. 3.12) on PMN, 
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monocytes, the putative precursor cells for DC, and both circulating and lung 
DC are in line with recent results published by other authors [120, 136]. In the 
present study, the expression of L-selectin (CD62L) by monocytes and DC was 
only partial, but could not be attributed to an established subset. The expression 
of adhesion molecules was assessed in both vehicle- and Flt3L treated mice 
and did not show any changes in response to Flt3L. 
Based on the phenotyping, a panel of function-blocking monoclonal antibodies 
was tested for inhibition of Flt3L elicited recruitment of DC and PMN in lung 
homogenate. Although there is a large body of literature investigating monocyte 
and PMN recruitment, only little is known about the adhesion molecules 
mediating DC recruitment to the lung [120]. The analysis showed that the Flt3L 
elicited recruitment of lung DC critically depended on β2 integrins. Since the 
common β2 integrin chain (CD18) is of crucial importance for almost all 
leukocyte recruitment processes in mammalian bodies [88], the blocking effect 
of anti-CD18 mAb confirms the report by Schneeberger et al. that gene deletion 
of CD18 in mice significantly lowers numbers of lung DC [137] and can be 
considered as a positive control for an effective application of the blocking 
antibodies. The β2 integrin chain/CD18 forms heterodimers with α integrins in 
vivo; both main dimerization partners for CD18, aL integrin (CD11a) and αM 
integrin (CD11b), are also critically involved in recruitment of lung DC. This is in 
line with previous reports about monocyte recruitment under steady-state and 
inflammatory conditions [120, 121]. A blockade of the third β2 integrin 
dimerization partner, αX integrin (CD11c), was not undertaken, since gene 
deletion studies have not provided evidence for any overt difference in DC 
numbers and function in these animals [138]. In an in vitro model with human 
monocyte-derived DC, blocking of CD11a and CD11b, but not of CD11c 
inhibited adhesion of the DC to vascular endothelial cells [139]. Furthermore, at 
least on circulating PBMo, CD11c is only expressed on a minor subpopulation 
(see Fig. 3.12 and [120]).  
Surprisingly, neither the blockade of α4 integrin (CD49d), which forms together 
with the β1 integrin chain VLA-4, the most important β1 integrin complex for 
monocyte recruitment, nor blockade of its main interaction partner on 
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endothelial and epithelial cells, VCAM-1 (CD106), had any impact on DC 
recruitment. This is in marked contrast to what has been reported for monocyte 
recruitment, where the interaction between VLA-4 and VCAM-1 is of crucial 
importance in both steady-state and inflammatory recruitment to the lung and to 
the alveolar space in vivo [121] and for the monocyte migration over alveolar 
epithelial cells infected with Influenza virus [140]. 
When analysing PMN recruitment to the lung after Flt3L treatment, previously 
published results by Maus et al. could be confirmed that the inflammatory 
recruitment of PMN to the lung depended mainly on CD11b and was not 
significantly affected by the blockade of CD11a and VLA-4 [121]. This seems to 
be a lung specific phenomenon, since reports by other groups using targeted 
gene deletion of the CD11a and CD11b genes have demonstrated an important 
role for CD11a in PMN recruitment in models of air pouch skin inflammation and 
thioglycollate-induced peritonitis [141, 142]. Whether these differences are due 
to differences in the recruitment pathways in different organs or can be 
explained by a compensatory upregulation of other α integrins in gene-deleted 
mice remains an open question. 
The α/β integrins on leukocytes can bind to several molecules on endothelial 
and epithelial cells, including members of the IgG superfamily, like the 
intercellular adhesion molecules (ICAMs) and vascular cell adhesion molecules 
(VCAMs), and to members of the junction adhesion molecule (JAM) family. In 
vitro, for many interactions of integrins with their counterreceptors an 
importance for leukocyte transmigration has been demonstrated [120, 143, 
144]. However, since most of the integrins on leukocytes have more than one 
interaction partner on the endothelial and epithelial side [143], a blockade or 
targeted gene deletion of members of the IgG superfamily often has no clear in 
vivo effect. In accordance with these observations, in the current study, the 
blockade of ICAM-1 (CD54) and VCAM-1 (CD106) had no significant effect on 
Flt3L elicited lung DC recruitment. This confirms findings by others where 
numbers of lung DC were not affected in ICAM-1 knock-out mice [137]. Also, 
blockade of JAM-C, which interacts mainly with CD11b [122], partially, but not 
significantly altered DC recruitment.  
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A third important family of adhesion molecules are the selectins, consisting of 
three members, E-, L- and P-selectin. Since L-selectin (CD62L) is only 
expressed by a small subset of circulating monocytes and DC, it was not 
considered as a possible target. The ligand for endothelial P-selectin, PSGL-1 
(CD162), is homogenously expressed on PBMo and DC. However, a recent 
report demonstrated no significant role of PSGL-1 for recruitment of circulating 
immature DC to inflamed skin [145]. Furthermore, in a model of allergic 
inflammation after intratracheal instillation of sheep erythrocytes, no recruitment 
defect for DC was reported in mice with a double targeted deletion of E- and P-
selectin [54]. Thus, a blockade of selectins as an intervention strategy was not 
pursued. 
Given these results, blockade of CD11a was chosen for selective inhibition of 
Flt3L elicited DC recruitment in the following experiments investigating the 
acute inflammatory potential of lung DC. In addition, a recent publication 
demonstrated an important role of CD11a but not CD11b for the transmigration 
of both CD11bpos CD8αneg myeloid DC and CD11bneg CD8αpos lymphoid DC 
over resting and TNF-α stimulated endothelial cells in vitro [146], collectively 
demonstrating an important role of CD11a in the inflammatory myeloid DC 
recruitment process.  
In the next step, the recruitment of DC and PMN after intratracheal LPS 
challenge in Flt3L- and vehicle-treated mice was analysed. LPS challenge in 
vehicle-treated mice led to a slight, but significant increase in DC numbers in 
lung homogenate, consistent with previous reports [51, 147]. PMN numbers 
increased moderately in an amount comparable to Flt3L treatment alone. In 
Flt3L pre-treated mice, LPS challenge led to a massive additional recruitment of 
both DC and PMN to the lung parenchyma. This LPS-induced DC recruitment 
also depended on CD11a and was not affected by CD49d blockade. Notably, 
anti-CD11a treatment in Flt3L plus LPS treated mice did not affect the lung 
parenchymal neutrophil recruitment, but rather reduced the transepithelial 
migration of elicited neutrophils, indicating that these two steps of alveolar 
reruitment of circulating PMN depend on different mechanisms. 
Taken together, these results confirm and expand previous reports by 
demonstrating that the Flt3L-elicited lung DC accumulation both in the absence 
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and presence of co-applied LPS is mediated by the β2 integrin CD11a but not 
the β1 integrin CD49d. Of note, both numbers of lung parenchymal and alveolar 
accumulating DC and neutrophils were synergistically increased in Flt3L 
pretreated mice co-challenged with LPS. 
 
4.4  Aggravated lung inflammation to LPS in Flt3L pretreated 
mice 
The analysis of the inflammatory phenotype after intratracheal LPS challenge 
showed in vehicle-treated mice a pronounced alveolar recruitment of PMN, 
combined with only a slight increase of alveolar DC in the absence of 
lymphocytes; a minor increase in alveolar leakage; and a modest release of 
TNF-α and IL-12. These findings are consistent with previously published 
results by others [118, 123-125]. In marked contrast, intratracheal LPS 
challenge of Flt3L pre-treated mice, in addition to the massive recruitment of DC 
and PMN to lung homogenate, led to a severely aggravated inflammatory 
phenotype as compared to vehicle-treated mice. In the BAL, the total numbers 
of leukocytes, the PMN, alveolar DC and lymphocytes were massively elevated. 
TNF-α levels were modestly and, most strikingly, IL-12 levels excessively 
increased. Furthermore, these mice displayed a severely aggravated leakage. 
By concomitant anti-CD11a mAb application, all of these findings could be 
reverted to the levels seen in vehicle-treated mice after LPS challenge. In 
contrast, blockade of VLA-4/CD49d had no effect. Importantly, both cytokine 
liberation in the BAL fluid and leakage persisted after neutrophil depletion. 
Although neutrophils per se are well accepted to mediate lung permeability 
changes in various models of acute lung inflammation [94, 99], the currently 
presented data strongly support the concept that in addition to neutrophils, lung 
DC may also play a critical role in determining the lung barrier integrity in 
response to acute lung inflammation. This concept is supported by two central 
observations: First, transient neutropenia was highly effective in depleting both 
lung parenchymal and alveolar accumulating neutrophils, while both 
proinflammatory mediator release and lung permeability in response to Flt3L 
plus LPS challenge were not affected. This indicated a minor role of lung and 
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alveolar neutrophils in induction of lung permeability in the presented model. In 
contrast, anti-CD11a treatment of the mice to block lung parenchymal and 
alveolar DC accumulation in response to Flt3L plus LPS was highly effective in 
reducing BAL fluid TNF-α and IL-12 levels and lung permeability changes, while 
numbers of interstitial PMN in lungs were not and numbers of alveolar recruited 
PMN were only partially affected. Furthermore, both the TNF-α and IL-12 
release and the lung permeability changes in mice without Flt3L pretreatment 
did not differ significantly between neutropenic and control mice. Collectively, 
the presented findings define a novel, hitherto unrecognized role of lung DC in 
regulating the lung barrier integrity in response to bacterial toxins and Gram-
negative pneumonia. As such, the presented data provide a possible 
explanation for the clinical observation that critically ill, neutropenic patients are 
known to develop ARDS, a clinical complication associated with a severe loss 
of lung barrier integrity [89, 100, 101] (see also 1.4). An experimental hint for an 
neutrophil-independent leakage after LPS stimulation has been provided by 
Tasaka et al., who showed that priming with Bacillus Calmette Guerin (BCG) 
severely enhanced the leakage after LPS challenge in guinea pigs also in 
neutrophil-depleted animals [148]. 
An important observation was that this severe aggravation of the pulmonary 
inflammatory phenotype after LPS challenge is not present in a model of LPS-
induced peritonitis. Although Flt3L pre-treatment elicited an increase in DC 
numbers in the peritoneal cavity, the inflammatory phenotype after 
intraperitoneal LPS in respect to total cell numbers, neutrophil numbers and DC 
count did not differ between Flt3L-pretreated and vehicle treated mice (see Fig. 
3.27). This indicates a fundamental difference between the pulmonary and 
peritoneal reaction pattern to LPS challenge and suggests also a different role 
of Flt3L-elicited DC in these two compartments. 
As outlined in the Introduction section (see 1.4), the secretion of cytokines after 
an inflammatory stimulus is crucial for the development of lung inflammation. It 
had to be defined in the current model whether the modest increase in TNF-α 
levels and the dramatic increase in IL-12 levels in BAL fluid in Flt3L pre-treated 
mice resulted in the mere increase in DC numbers, or whether Flt3L elicited DC 
display a higher capacity of producing proinflammatory cytokines. 
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When analysing the production of TNF-α and MIP-2 mRNA in lung DC and lung 
Mφ in vivo after intratracheal challenge with LPS, it could be shown that both 
population actively take part in the production of these classical pro-
inflammatory cytokines.  However, when flow-sorted lung DC from Flt3L and 
vehicle-treated mice were stimulated in vitro with LPS, there was no support 
that Flt3L directly modulates this LPS responsiveness of lung DC to produce 
TNF-α and MIP-2. Sorted lung DC from both groups of mice had similarly 
increased TNF-α and MIP-2 mRNA levels (see Fig. 3.29). 
In marked contrast, the capability of lung DC to produce IL-12 p35 was 
significantly higher in DC from Flt3L-pretreated as compared to vehicle-treated 
mice. This increased capability of Flt3L elicited DC to produce higher amounts 
of IL-12 has been described by others before; the enhanced production leads to 
an increased skewing of T cells in a Th1 direction [149, 150]. This can be 
further enhanced by co-treatment of mice with Flt3L and anti-IL-10 antibodies 
[151]. However, the exact mechanisms underlying this observation remain to be 
elucidated.  
Studies comparing human and mouse DC that have been isolated from Flt3L- 
versus vehicle-treated individuals have shown differences in the biologic 
behaviour of these cells, e.g., in respect of maturation stage and profile and 
amount of cytokine production after stimulation [134, 152]. However, the 
complete relevance of these findings has to be further clarified in future 
investigations. Also, the exact role of different cytokines on in vivo DC 
generation, subset composition, cytokine production, and T cell stimulation 
capacity remains controversial [74, 153].  
However, the synergistic effect of Flt3L plus LPS treatment on the lung DC pool 
and the concomitant lung barrier dysfunction was noted within a 24h post LPS 
application period. The recruitment of DC to the airways after an inflammatory 
stimulus has been shown to take place within hours after stimulation [51, 52] 
[53]. Because Flt3L pre-treatment of mice is known to increase numbers of 
circulating monocytes and circulating DC acting as myeloid DC precursor cells, 
it appears likely that Flt3L elicited lung parenchymal DC upon LPS challenge 
additionally promote a rapid mobilization of circulating myeloid DC precursor 
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cells into both the lung parenchymal and alveolar air space that ultimately 
contribute to an aggravated lung inflammatory response.  
 
4.5  Klebsiella pneumoniae infection in Flt3L pretreated mice 
Although recognition of LPS by TLR4 is one of the critical steps in initiating an 
effective immune response in Gram-negative pneumonia [154, 155], LPS 
instillation alone does not reflect fully the complex situation in bacterial 
pneumonia. Therefore, an intratracheal infection model with K. pneumoniae was 
used to evaluate the role of Flt3L pretreatment in acute pneumonia. By this, the 
finding that Flt3L pre-treatment aggravates the lung inflammation in response to 
intratracheal LPS challenge could be confirmed. Furthermore, and in constrast 
to the findings after LPS instillation, the mice that were pretreated with Flt3L 
before infection showed an increased mortality, whereas all vehicle-treated 
mice were able to control the infection and survived the challenge (see Fig. 
3.26). Like in the LPS challenge model, mice that had been pretreated with 
Flt3L displayed a severely aggravated alveolitis with increased leakage. 
These findings were confirmed by a very recent report in a model of Gram-
positive pneumonia with Streptococcus pneumoniae infection [156]. The 
increase in mortality in models of acute bacterial pneumonia after Flt3L 
pretreatment is in marked contrast to most reports by other authors addressing 
the mortality after Flt3L treatment in other infection models. Toliver-Kinsky et al. 
described a better survival of Flt3L treated mice in a model of Pseudomonas 
aeruginosa superinfection of burn wounds. A central role for Flt3L elicited DC in 
this model was demonstrated by the fact that adoptive transfer of splenic DC 
from Flt3L pretreated, but not from vehicle-treated, mice improved survival after 
burn and P. aeruginosa infection [78]. According to earlier published results, this 
effect may be due to a restoration of the secretion of IL-12 and interferon-γ in 
burned mice after Flt3L treatment [150]. Another possible explanation may be 
that Flt3L can reverse endotoxin tolerance-related immune paralysis, a disease 
state that can develop after sepsis, major trauma, or burns [80]. Flt3L pre-
treatment also improved survival in infection models with Listeria 
monocytogenes [76, 77]; however, other researchers have reported an 
increased L. monocytogenes burden in Flt3L pretreated mice [81]. In other 
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models, Flt3L treatment had no or even adverse effects: The outcome of 
Pneumocystis carinii pneumonia in rats was not affected by Flt3L treatment 
[157]; and bacterial burden and mortality was significantly higher in Flt3L treated 
than in vehicle-treated mice after infection with Mycobacterium tuberculosis 
[81].  
In summary, the findings of this study point to the necessity to explore potential 
organ-specific effects, in this case of the lung, before applying a systemic 
immunomodulatory treatment. This is also underlined by the finding that, in 
marked contrast to the situation in the lung, Flt3L pretreated mice did not show 
an enhanced inflammatory response after intraperitoneal LPS challenge. 
 
4.6  Conclusion and future perspectives 
In the current study it was undertaken to evaluate the role of lung DC in a model 
of acute lung inflammation. Cumulatively, the data show that the β2 integrin 
dependent Flt3L elicited accumulation of DC in the lung parenchymal 
compartment triggers an acute lung injury upon both E. coli endotoxin and 
infection with K. pneumnoniae. This acute lung injury is characterized by an 
increased neutrophilic alveolitis, proinflammatory mediator release, a high 
increase in lung permeability, and, in case of K. pneumoniae infection, also an 
increased mortality. 
Recent studies have addressed the effect of Flt3L treatment as 
immunotherapeutic option to antagonize chronic or systemic infections, to 
reverse airway changes in asthma, or as an adjuvant treatment in radiation 
therapy of cancer [70, 75-77, 79, 158]. Bearing in mind the results of the current 
study, immunoregulatory or tolerogenic strategies modulating the numbers 
and/or functions of DC pools to optimize immune responses of the lung to 
inhaled inflammatory or infectious antigens need to reflect the considerable 
proinflammatory potential associated with the lung DC pool. 
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Some aspects of the observed aggravation of lung inflammation after Flt3L pre-
treatment and of the proposed central role for DC in initiating and skewing an 
acute lung inflammation appear to be interesting for more detailed 
investigations in following projects. Questions to be asked could be: 
 
(i) What are the exact mechanisms by which DC control the lung barrier 
integrity? How can these mechanisms be addressed in terms of an 
intervention strategy? 
(ii) Can these findings be reproduced in a model of specific depletion of lung 
DC without the (rather artificial) prior enrichment by Flt3L application? 
For answering this question, in a first step a model of efficient depletion 
of lung DC would have to be established, e.g. by using bone-marrow 
chimera of wild-type and CD11c-diptheria toxin receptor transgenic mice 
[61]. 
(iii) Could DC be targeted by pharmacologic agents to modify their role in 
acute bacterial pneumonia? 
(iv) Does the initiation of an acute lung inflammation require a direct sensing 
of PAMPs and/or bacteria by DC, or are DC activated in a secondary 
step by other sentinel cells (then presumably alveolar macrophages 
and/or alveolar epithelial cells)? 
(v) How are DC integrated in the close anatomical network in the alveolar 
space? Which are the factors that allow communication between alveolar 
macrophages, epithelial, endothelial and stroma cells? What role do DC 
play under steady-state conditions in this network? 
(vi) What is the role of this network in the later course of the inflammation, 
i.e. in the resolution and repair phase of an acute pulmonary infection? 
 
The main mechanisms of Flt3L-elicited DC migration and of the acute 
inflammatory potential of lung DC, as well as the questions arising from these 
findings, have been visualized and summarized in Fig. 4.1. 
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Fig. 4.1: Schematic outline of the major findings and the possible future perspectives 
presented in this thesis 
(A) DC precursors emigrate from the blood into the lung tissue mainly by using β2 integrins and 
differentiate within the lung into immature DC. They reside in close proximity to the alveolar 
space and the small capillaries. (B) Immediately after the alveolar space has been invaded by 
pathogens, DC come into contact with them. By this, DC are rapidly activated to produce high 
amounts of proinflammatory cytokines, such as TNF-α, MIP-2, and IL-12. Moreover, they initiate 
a dysfunction of the capillary walls, resulting in an increased leakage of blood constituents into 
the alveolar space. (C) As outlined in the text, there are open questions remaining, e.g., (i) how 
are DC integrated into the close network of other leukocyte populations in the lung, namely 
resident alveolar macrophages, under acute inflammatory conditions? (ii) Is there a cross-talk 
between lung DC and alveolar epithelial type II cells, which present a major source of cytokines 
during acute inflammation? (iii) What are the exact mechanisms of the induction of the alveolo-
capillary leakage? 
A 
B C
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5  Summary 
5.1  Summary 
Dendritic cells (DCs) are important regulators of the immune system and are 
critically involved in the immunosurveillance of the lung. They reside in close 
proximity to both the large airways and the alveoli and constantly take up and 
process antigen. While many aspects of lung DC biology in adaptive immune 
responses have been addressed, their role in acute bacterial pneumonia is less 
well understood. Their unique equipment with receptors and effector molecules 
of the innate immune system, however, and their capacity to produce large 
amounts of both proinflammatory and immuneregulatory cytokines within the 
first hours after antigen contact raises the question of the contribution of lung 
DC to the initiation and course of the early phase of bacterial pneumonia. 
Another question that has been only partially adressed is the contribution of the 
different adhesion molecules for DC recruitment to the lung under non-
inflammatory and inflammatory conditions. 
To address these questions, mice were treated systemically with Fms-like 
tyrosine kinase-3 ligand (Flt3L), the most important in vivo growth factor for DC 
proliferation and differentiation. The contribution of adhesion molecules were 
analyzed by coapplication of function-blocking monoclonal antibodies against 
various adhesion molecules. Flt3L treatment of mice elicited a strong lung DC 
accumulation that was mainly dependent on β2 integrins, blockade of which led 
to a >80% reduction of DC numbers in lung homogenates. In contrast, blockade 
of both β1 integrin CD29/CD49d and VCAM-1 did not affect Flt3L elicited lung 
DC accumulation. 
Intratracheal challenge with lipopolysaccharide resulted in a much more severe 
inflammatory response in the lung of Fl3L pretreated than of vehicle-treated 
mice, as demonstrated by increased leukocyte numbers in lung tissue and 
bronchoalveolar lavage; moderately increased TNF-α and dramatically 
increased IL-12 levels; and, most importantly, a severe aggravation of the lung 
leakage. This aggravated inflammation could be inhibited by anti-CD11a-
mediated inhibition of Flt3L elicited lung DC accumulation, but persisted after 
depletion of neutrophils, indicating a novel, hitherto unrecognized role of lung 
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DC in the regulation of the lung barrier integrity. Importantly, these findings 
could be confirmed in Klebsiella pneumoniae infection model, where Flt3L 
pretreated mice did not only exhibit a severely aggravated inflammation, but 
also an increased mortality compared to vehicle-treated mice.  
Taken together, the results of this study shed a new light on the role of lung DC 
in the initiation and the early phase of acute bacterial pneumonia, and expand 
and partially redefine the pathophysiologic concept of acute lung inflammation.  
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5.2  Zusammenfassung 
Dendritische Zellen (DC) sind wichtige Regulatoren des Immunsystems und 
sind zentral in die Abwehrfunktion der Lunge integriert. Sie sind in enger 
Nachbarschaft zu den großen Atemwegen und den Alveolen lokalisiert und 
phagozytieren und prozessieren kontinuierlich Antigene. Viele Aspekte der DC-
Biologie in der Lunge und ihrer Rolle in der adaptiven Immunantwort sind 
eingehend untersucht worden; ihre Rolle in akuten Entzündungsreaktionen wie 
der akuten bakteriellen Pneumonie ist hingegen bisher kaum bekannt. DC sind 
mit einer einzigartigen Vielzahl von Rezeptoren des angeborenen 
Immunsystems bestückt und sind außerdem in der Lage, innerhalb der ersten 
Stunden nach Antigenkontakt große Mengen proinflammatorischer und 
immunregulatorischer Zytokine zu produzieren. Dieses wirft die Frage auf, 
inwieweit DC an Initiierung und Verlauf der frühen Phase einer bakteriellen 
Pneumonie beteiligt sind. Nur teilweise bekannt ist ferner der Beitrag 
verschiedener Adhäsionsmoleküle zur Rekrutierung von DC in die Lunge unter 
Ruhe- und Entzündungsbedingungen. 
Zur Beantwortung dieser Fragen wurden Mäuse systemisch mit Fms-like 
tyrosine kinase-3-Ligand (Flt3L), dem wichtigsten in vivo-Wachstumsfaktor für 
die DC-Differenzierung, behandelt. Der Beitrag verschiedener 
Adhäsionsmoleküle zur DC-Rekrutierung wurde durch Gabe von 
funktionsblockierenden monoklonalen Antikörpern untersucht. Die Gabe von 
Flt3L führte zu einer starken Anreicherung von DC in der Lunge; diese 
Rekrutierung war abhängig von β2-Integrinen, während die Blockade des β1-
Integrins CD29/CD49d und seines Interaktionspartners VCAM-1 keinen 
blockierenden Effekt hatte. 
Die intratracheale Gabe von Lipopolysaccharid führte in Flt3L-vorbehandelten 
Mäusen zu einem dramatisch verstärkten Entzündungsphänotyp im Vergleich 
zu den Kontrollen, ablesbar an einer deutlich höheren Zahl von Leukozyten im 
Lungengewebe und in der bronchoalveolären Lavage, einem moderaten TNF-
α- und dramatischen IL-12-Anstieg und einer schweren Schädigung der 
alveolokapillären Schrankenfunktion. Diese aggravierte Entzündung konnte 
durch eine Blockade der DC-Anreicherung in der Lunge durch anti-CD11a-
Antikörper auf das Niveau der kontroll-behandelten Mäuse reduziert werden, 
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persistierte aber nach einer Depletion der neutrophilen Granulozyten. Dieses 
zeigt eine neue, bisher unbekannte Bedeutung von DC für die Regulation der 
Schrankenfunktion in der Lunge. Diese Befunde konnten in einem 
Infektionsmodell mit Klebsiella pneumoniae bestätigt werden. Auch in diesem 
Modell zeigte sich eine starke Verstärkung der Entzündungsantwort in Flt3L-
vorbehandelten Tieren, zudem wiesen diese Tiere eine deutlich erhöhte 
Mortalität gegenüber den Kontrolltieren auf. 
In der Zusammenschau zeigen die Ergebnisse der vorliegenden Untersuchung 
eine neue, bisher unbekannte Funktion von DC der Lunge in der Initiierung und 
der frühen Phase bakterieller Pneumonien. Darüberhinaus erweitern und 
modifizieren diese hier präsentierten Ergebnisse das bisher bekannte 
pathophysiologische Bild dieser wichtigen Erkrankung.  
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